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RESUMÉ 
It is hoped that xenotransplantation may be a method of alleviating 
the severe shortage of donor organs so that th e t housands of humans 
who die yearly while awaiting transplants can be saved. 
In an attempt to protect both public and patient against rejec ti o n 
and di sease transmission, donor animal s a re bei ng genet i c a J 1 y 
modified and specially bred . This presents a multitude of 
scientific , legal and ethical problems which have resul ted in a 
cali for a moratorium on clinical trials . 
In evaluating the necessity for such a moratorium, this essay 
attempts to assess the risks to patient and public, looks at the 
legal protection available to the animal and human, analyzes the 
ethical issues of genetically modifying and sacrificing animals so 
that humans may live, and considers the issue of commercialisation 
of living matter . 
On espère que la xenotransplantation peut serv1r comme technologie 
pour remplacer la manque des organes et sauver la vje des milliers 
qu1 meurent chaque année en attendant . 
Pour se battre contre le rejet et protéger le patient et le public 
contre les risques de la transmission des virus , on apporte les 
modification aux génes des animaux donneurs avant l ' élevage, ce qu1 
cause des prob l èmes scientifiques , légales et éthiques de toutes 
sortes , résultant dans une demande de moratoire sur les essals 
cliniques . 
Le but de cet essa1 est l ' évaluation de la necessité d ' une telle 
moratoire en regardant les risques pour le patient et le public, 
l es l ois déjà en place pour protéger les animaux et les humains , 
auss1 que les questions morales posées par les modifications 
appo r tées a u x génes des a n 1maux et par leur sacrifice pour 
favoriser la vie humaine , et pa r la rentabilité de manipulation de 
la matière vivante . 
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INTRODUCTION 
It is an undeniable fact that there is a severe shortage of 
organs available for transplantation. In the United States 
alone, there were approximately 52,000 patients awaiting 
transplants in 1998, and it is reported that several thousand 
die every year while waiting. Statistics provided in Time 
Magazine 1 state that, as of the first week in August 1996, 
47,000 Americans were on transplant waiting lists, while thére 
had only been enough organs available during the whole of 1995 
for a total of 19,136 transplants. In the United Kingdom 
there were 6133 people awaiting organ transplants in 1995, 
\ 
whereas ànly 3480 organs were donated and 3161 transplanted 
that year. 2 In spite of the obvious need it is estimated 
that only 30%-40% of potential cadaveric organs are procured. 
Xenotransplantation, namely, a procedure that involves the use 
of living cells, tissues or organs from a non human animal 
source for transplantation, implantation or ex vivo perfusion 
1n humans, is being studied as a possible solution. 
Brain cells of a foetal pig have been used to treat 
Parkinsons, baboon marrow has been transplanted into an AIDS 
patient, diabetes patients have received encapsulated pig 
pancreas cells, p1g skin transplants have been used for 
serious burns, and outside perfusion using pig livers serves 
as a bridging deviee while awaiting donor livers. 
Between 1968 and 1984 there were six xenotransplants performed 
including Baby Fae who survived 20 days with a baboon heart. 
In 1992 the liver of a 15 year old baboon was transplanted to 
a 35 year old male AIDS patient who survived 70 days, and on 
January 19th, 1993 a baboon liver was transplanted to a 62 
year old who survived for 25 days but in an unconscious state, 
A poll released by the National Kidney Foundation in January, 
1998 showed that 62% of Americans favour xenotransplantation 
and 75% of primary care physicians and transplant surgeons see 
2 
it as the best way of alleviating organ shortage. Yet there 
are th~se who call for a moratorium until control of disease 
transmission can be assured and public acceptance ascertained. 
This paper attempts to address sorne of the scientific, legal 
and ethical problems associated with xenotransplantation. For 
clinicians, the main problem is rejection. For scientists 
doing pure research, the problem is to identify, control and 
prevent the transmission of zoonotic disease. For the 
legislators there remains the gargantuan task of regulating 
the breeding, maintaining and distributing of genetic ally 
modified donor animals, establishing who c an undertake the 
process and under what conditions, and protecting the public 
from the possible nefarious social and heal th consequences 
foreseen by certain scientists and ethicists. 
Ethicists also have an important role to play. Part of the 
technology includes the genetic manipulation of the donor 
animal. This in itself instills fear and uncertainty; fear of 
possible monsters to be generated as a result of interference 
with natural creation, fear that by modifying the genetic 
component of an animal we are usurping the power of God, 
uncertainty as to who shall wield the power and how it is to 
be controlled. 
The objectives of xenotransplantation are worthy and 
desirable, but does the end justify the means? Are we 
exploiting animals by sacrificing them for the health needs of 
man? Are we placing many at risk to save a few? Are we 
devaluing the meaning of life by defining it in terms of 
organs and cells? What gives us the right to value our lives 
more than those of the animals whose organs we harvest? 
3 
scientific knowledge leads to new technology the use of which 
must be approved by Community Standards which are reflected 1n 
regulatory limits imposed by law. We must look to the law to protect our collective rights. Xenotransplantation must be 
controlled so as to assure public safety and prevent 
exploitation and abuse. It must be regulated 1n order to become acceptable by community standards. 
In attempting to assess the necessity for a moratorium, this paper will look at the health risks both to the individual and 
the public; at the roles to be played by the animal donors and human recipients; at the validity of the process itself from 
an ethical and moral point of view and at the need for further 
regulation. 
The basic question then becomes: Are sufficient protection 
and control provided by the law and the principles on which it 1s based so as to render xenotransplantation a method of treatment acceptable both to the scientific community and the public at large? 
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ENDNOTES TO INTRODUCTION 
1. B.D. Colen, "Organ Concert", Time, vol. 148, No. 20, Fall 1996, 
p. 58 
2. "Animal Tissue into Humans", A Report by the Advisory Group on 
the Ethics of Xenotransplantation, Her Majesty's Stationery Office, 
1997, pp 47-48 
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CHAPTER 1 THE RISKS OF XENOTRANSPLANTATION 
At this time, the animal of choice as organ donor for humans 
is the pig. However, it has been demonstrated that retrovirus 
from the porcine cell line can infect human cells. It is a 
prerequisite for research on human subjects that the risks not 
outweigh the benefits. The issue of potential risk from 
xenotransplantation must therefore be addressed. 
1. KNOWN RISKS 
Animal diseases whi c h affect humans are referred to as 
zoonos1s. Well known cases include rabies, malaria, anthrax 
and Lyme disease. A recent article 1 reports that i t has 
been demonstrated that 
retroviruses (PERVs) are 
two sets of porc1ne endogenous 
capable of 1n vitro replication in 
certain human cell lines. These PERVs are expressed in the 
spleen, kidney, heart, primary aortic endothelial cells, skin 
and lung. The data shows that at least most of all 
transplanted porcine tissues will express one or more 
retroviruses capable of infecting human cells, and because of 
the way they are inherited, it will be impossible to eliminate 
them from source herds. This does not prove that any such 
vi ruses would, in fact, be transferred from a transplanted 
organ; but the potential must be considered. 2 Research to 
date on diabetic patients who have received porc1ne fetal 
islets, and on renal dialysis patients with short term 
extracorporeal vascular connection to pig kidneys, has not 
revealed any transmissison of PERV infection even over a 
lengthy period of time. Consequently, current data would 
indicate that PERVs will not show a high rate of transmission. 
In addition, to the concern over PERVs, parasitic hazards have 
been identified, and swine prions are known to be 
transmissible to man. 3 Also, recent serological studies in 
2 
France have suggested the possibility of porcine pseudo rabies 
virus transmission to human recipients of porcine cells.
4 
The British Advisory Group on the Ethics of 
Xenotransplantation concluded in its report: 
" th t th 1"s 1"nsufficient knowledge about the known . . . a ere 
viruses to made it 
the current time. 
porcine endogenous 
safe to proceed to clinical trials at 
This is particularly relevant to the 
. " 5 retrov1ruses. 
Health Care Canada, in an information bulletin dated November, 
1997 states: 
"No medical procedure is without risk. Before 
xenotransplantation could be considered in Canada, strict 
safety standards would have to be met. Whether Canadians 
would feel comfortable accepting a degree of risk 1n 
return for the potential benefits of such transplant is 
still open to question." 6 
So long as these known risks have not heen fully clarified and 
cannot be controlled, they weigh heavily in any decision to 
permit experimentation on xenotransplantation and should be 
considered sufficiently dangerous at this time to prevent any 
clinical trials. 
2. UNKNOWN DANGERS 
A vascularized sol id organ is the most efficient means of 
transmitting a viral infection. 7 The critical question is 
whether there are many such viruses we do not know about. 8 
That there is potential for disaster is illustrated by the 
fact that millions of people were exposed to simian virus in 
the 1950s after the inadvertant contamination of polio and 
3 
adenovirus vaccines made in monkey cells. This arase through 
a lack of adequate scientific knowledge. 
Viruses are difficult to diagnose and control in animal herd s 
and once transferred from pig to immunocompromised human, the 
behaviour of the porc1ne endogenous retrov irus ls as yet 
uncharacterized. In other words , the pathog e ne sis o f th e 
virus may be modified by the genetic recombination of swin e 
viruses with those in the rec ipient. Furthermore , trans fe r t o 
humans of an endogenous retrovirus could c r eate a hybr i d 
better adapted to survival, replication and pathogenicity in 
the human host. 9 
Sorne Vlruses are known to be spec 1e s specifie; that lS, an 
animal organ may be immune to a human virus, or an animal 
virus may be latent in the donor animal and become virulent in 
the human recipient. Moreover, wh ere no rea c tivity is noted, 
it may be because of test limitations rather than because of 
a lack of reaction. 
Scientists Michele Pearson and William Jarvis express the 
concern that a retroviral infection may be transmitted, 
followed by clinical latency, so as to permit the infectious 
agent to transmit silently and bec ome established ln the 
population before being recogniz e d. They also worry that a 
combina tian of zoonotic and human strains may r e sul t ln a 
variant of uncertain virulence and pathogenicity. Such 
potential zoonoses are as yet unknown and no standaradized 
tests are available for their detection. 
JO 
Another group of scientists headed by Bach and Fishman compare 
the risks of xenotransplantation with those of 
allotransplantation and find them to be especially great in 
the case of xenotransplantation for the following reasons: 
4 
1. the suppression of the 1mmune system may be greater; 
11 . because organisms benign in the donor may activate in 
the recipient or cause nove] and unreco gnized clinical 
syndromes; 
111 . the host ' s susceptibility may be altered by 
transplantation treatment; 
iv. there may be no microbiologie assays to detect such 
transmitted organ1sms; 
v . Clinical symptoms may not be recognized. 11 
Scientists Borie and Cramer 1ssue th e ir warn1ng: 
"It appears that the microbiological status of p1gs 1s, as 
yet, not sufficiently characterized to allow for widespread 
application of this technology ( xenotransplantation). Porcine 
retroviruses and probably prions as well, are potentially 
dangerous agents that could be transmitted to man . Studies 
characterizing the behaviour of pig retroviruses following 
xenotransplantation to another spec1es will have to be 
examined carefully. Furthermore, the tools for accurate 
diagnosis of the human infection with pig pathogens will have 
to be developed. Indeed, most current serological tests 
probably are of limited value in immunosuppressed patients, 
which emphasizes the need for new generations of molecular 
biology based technologies. Concomitantly, more precise 
estimates of the risk transmission of a pig pathogen from an 
infected recipient of a xenotransplant to the general 
population will have to be gathered. Even though there is 
widespread agreement that the risk 1s probably small, the 
potential for new pandemies has led bath authorities and 
workers involved in the field to consider very seriously the 
issue of xenozoos1s possibly linked with p1g 
xenotransplantation." 
"Indeed, even though the risk 
limited this risk is real 
5 
of inadvertant zoonoses appears 
and will have to be weighed precisely against the advantages of the utilisation 
1 . " 12 
on a large 
scale of pig organs for transp antat~on. 
3. PUBLIC DANGER 
Another major concern ~s the transmission of the porc~ne pathogen not only to the recipient, but to the public at large. Although we know that there are pig retroviruses that 
· 
· a· h 13 t 
affect human cell s ~n laboratory Petr~ ~s es, we canno know their effect in a living human until transmission has occured, and infectious diseases can lay dormant for years. If an unknown disease did occur, it would be necessary to quarantine the infected individual as well as those with whom he had been in contact. The British are taking no chances and have set up the Xenotransplantation Interim Regulatory Authority to regulate all developments and procedures until such time as there shall be primary legislation. 14 
Jonathan Allan 15 sat on the FDA panel which formulated the regulations in the U.S.A. He feels that the risk is presently non quantifiable. But because it cannet be measured does not. mean it should be ignored. Once a new virus is unleashed it becomes a monumental task to identify it, develop adequate screen~ng tests and prevent its spread. 
The question therefore arises, can we breed donor ani mals carefully enough to avoid disease transmission? What should we be doing so as not to impede scientific progress while attempting to protect the recipients and the public? 
6 
Pearson, Jarvis et a1 16 believe that only with systematic 
collection of data on xenotransplantation recipients will we 
be able to know if the residual risks are outweighed by the 
potential benefits. In order to minimize infectious risk, 
they suggest the following: 
1. Rigorous scientific review of all protocols; 
2. A plan to monitor infections; 
3. A standardized approach for selecting and screening animal 
èonors; 
4. Development of lists of potential infectious agents; 
5. National and international consensus standards to ensure 
quality and safety of xenotransplantation clinical trials; 
6. A national registry (centralized data base) to evaluate 
long term safety. 
One of the main concerns of Borie, Cramer, et al 17 is that 
bacterial hazards may not be indentified through standard 
clinical microbiological techniques and they emphasize the 
necessity of having a veterinary microbiological lab available 
at xenotransplantation sites. 
In the United States, Jonathan Allan emphasizes that 1n 
assessing the balance between risk and efficacy, public safety 
must weigh heavily. He advocates the necessity for Federal, 
as opposed to State, created and administered guidelines as he 
does not believe policing of transplant procedures can be 
effective at the local level. As a member of the FDA panel 
which approved the isolated case of implantation of baboon 
bone marrow into a human, he relates how influenced they all 
were by the emotional pleas _of the family and local community: 
7 
"And if a federal panel can be so heavily influenced by political expediency or desperation on the part o f a patient or community, it is not difficult to imagine that guidelines played out on the local level may be similarly influenced by 
0 d h d " 18 the urgency of these llfe-or- eat ramas. 
Although the issue of public safety appears to be of serious concern to most scientists working in the field, an optimistic feeling prevails. It lS generally felt that the public supports and will continue to support xenotransplantation trials so long as they are carried out with patient benefit i n mind. 19 
The conf 1 ict between public safety and indi vidual need lS perhaps best expressed by physician, Osca r Bronsther, who while acknowledging the existence of a non quantifiable risk to public health with xenotransplantation, also is aware that an additional one hundred thousand (100,000) patients in the United States alone could benefit from an adequate organ supply. He states: 
"As surgeons, we are commi tted to patients with life threatening illness. 
the needs o f our 
As citizens of the world, we must ensure that adequate scientific research is accomplished and that our knowledge of all aspects of xenotransplantation is developed exponentia lly wi th o ur desire to make xenografts clinically viable." 20 
As long as scientists continue searching for ways to test for, control and prevent the transmission of animal pathogens through organ transfer, xenotransplantation remains a potential medical treatment procedure. Meanwhile, we must prepare for the commencement of cross species organ transplantation experiments first with primates, and ultimately with humans. In chapters 2 and 3 we will look at how our legal structure protects animals and humans as subjects of scientific experimentation. 
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CHAPTER 2 - THE ANIMAL IN XENOTRANSPLANTATION 
1. INTRODUCTION 
At this tirne, the animal of choice as organ d o nor is the pig. 
In order to fight organ rejection, current practice lS to 
perforrn sorne genetic modification and then breed the rnodified 
pig for the purpose of becorning a donor. 
Would we ever use hurnans ln this way? would it be legally 
perrnissible? What about higher animal spec1es such as 
dolphins, apes, chirnpanzees? Are we, as a society, prepared 
to accept the process of xenotransplantation in the interest 
of science, or in the interest of saving lives? How do we 
evaluate the life of any one individual beside the life of any 
other? beside the life of any animal? Does the hurnan have an 
absolute right to life? to what extent and for how long? 
Does he have an obligation to preserve the life of the animal? 
under what circurnstances and to what extent? Can we attribute 
rights to anirnals, or only to man? Do we use nature, or do we 
protect it? Are these rnutually exclusive choices? 
If anirnals are capable of experiencing pain, if they are 
capable of feelings, of courage, of loyalty, we must question 
the nature of their role ln society, and study their 
contribution to scientific discovery as a function of that 
role and in the light of the true value of the scientific 
innovation for which they are sacrificed. 
Legally and ethically, animal abuse of any sort, under any 
circurnstance, is inexcusable and unacceptible. What we are 
considering are the pararneters of use perrnissible in order to 
obtain scientific knowledge and develop resultant technology 
beneficiai to man. We will look first at how, in our society, 
the law protects anirnals in general and research animals in 
particular and how cornrnunity standards accept and affect the 
use of anirnals as organ donors. 
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2. THE REGULATION OF ANIMAL USE 
A. Animal Rights 
The Universal Declaration of Animal Rights, 1 states 
? 
specifically - that scientific experimentation resulting 1n 
physical or psychological suffering violates the rights of 
animals, stated in the Declaration as the right to respect, to 
the attention and care of humans, to absence of pain and crue] 
treatment, to the freedom to live in their natural habitat, 
and to live out their natural life span free of exploitation, 
and to have their rights defended by law as are those of man. 
A society responds to its concerns through the laws it 
creates. Animal rights are manifested through man's 
corresponding legal obligations towards them. Our law 
legislates that we behave humanely towards all animais, 
nourish them and keep them free from pain, suffering and harm. 
B. The Canadian Criminal Code 
The criminal code makes it a criminal office to "wilfully" 
cause, or permit to be caused unneccessary pain, suffering or 
0 • t 0 1 3 lnJury o an an1ma • 
C. Regulations Respecting the Treatment of Animals 
Animals destined for human consumption are protected by 
regulation4 under the Law Pertaining to Inspection of Meat. 
They must be protected from unnecessary suffering, provided 
with adequate air and space, be appropriately fed and watered, 
and killed painlessly when their time cornes. 
3 
Abbatoires and animal transport vehicles are regulated by Food 
Regulation5 under the Law pertaining to Agricultural 
Products, Marine Products and Food. Animal auction bouses are 
governed by Regulation on the auction sale of Live Animals 6 
under the Law of Sanitary Protection of Animals. 
In March 1992, the report of the Round Table on Prevention of 
Cruel ty to Animal s was produced. 7 This group had been 
mandated by the Minister of Agriculture of Quebec to study, 
analyse and evaluate the problems and legislation pertaining 
to cruelty to animals and to provide recommendations for the 
improvement of its prevention of such cruelty. 
The committee set out to look at the relationship between man 
and animal in the light of the use made of the latter by the 
former for food, clothing, protection and entertainment. The 
report deals with minimum requirements for keeping animals, 
animals in research, public education on the ethics of man's 
relationship with animals, and proposals for potential 
legislation. Having reiterated the basic requirements for 
maintaining animals, namely, provision of sufficient food, 
water and space, creation of an environment corresponding to 
the needs of the animal, medical care and freedom from abuse 
and suffering, the committee looked at economies and research. 
The members of the Round Table accept the use of animals 1n 
research as inevitable, necessary and indispensable, but 
underline the necessity for rules to structure their use. 
They discuss the guidelines established by the Canadian 
Council on Animal Care (CCAC) as well as the surveillance 
exercised by that body, and conclude that an animal should not 
be considered in distress if such distress results from an 
activity practiced in conformity with generally recognized 
rules pertaining to teaching and research such as the 
guidelines established by the CCAC. A distressed animal is 
defined as one which lacks food, water or shelter, is wounded 
or ill, or subject to abuse or ill treatment. 
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D. The Guidelines of the Canadian Council on Animal Care 
The CCAC is a non profit, independant organization, created 1n 
1968, operating under the aegis of the Association of 
Universities and Colleges of Canada and funded by the Natural 
Sciences and Engineering Research Council and the Medical 
Research Council. Its purpose is the regulation and overseeing 
of the care and use of research animais 1n universities, 
hospitals, 
laboratories. 
extensive 
pharmaceutical compan1es and 
has 
government 
developed an 
imposed, 1n 
To achieve this end it 
set f "d 1 " 8 h" h o gu1 e 1nes w 1c are 
conjunction with local institutional animal care committees, 
through site visits and reports, and sanctioned by funding 
control. It also counsels and educates by means of its 
publications, conferences and training sessions. 
The CCAC lS dedicated to the humane care and use of research 
animal s. Its guidel ines are based on the princip! es of 
avoidance of unnecessary stress to the animal, use of the 
minimum number of animais and employment of in vitro systems 
wherever possible, use of the lowest possible forms of life, 
and research which lS justifiable. 
They are also based on the belief that, as humans, we are 
morally responsible for any living thing that we cause to be 
dependent upon us. Into this category fall animais used ln 
research. Consequently, exemplary standards of humane care 
and treatment must be exercised by every persan involved in 
the research process. 
From this premise come the following principles established by 
the CCAC: 9 
1. The research must fulfill the premise of a reasonable 
expectation that it will be of immediate or eventual benefit 
to Man or animais. 
5 
2. The animais must not be subjected to unnecessary pa in o r 
distress, and, where necessary, these should be minimi zed 1n 
bath intensity and duration. 
3. Any animal 1n severe pain which canna t be alleviated must 
be euthanized. 
4. Alternative end points to the death of the anima l are to 
be sought, and guidelines have recently been issued relevant 
to this topic. 10 
5. The witholding of food and water must be short term and 
non detrimental to the health of the animal. 
6. Physical restraint causing distress or ill effec ts lS to 
be avoided. 
7. The witholding of pa1n relieving medication, immobilizing 
experiments, electric shock and use of extreme environmental 
conditions are possible only as an exception, and the degree 
of pain inval ved must never exceed that determined by the 
humanitarian importance of the problem to be solved by the 
research protocol. 
The CCAC has also established detailed requirements for the 
housing and daily care and maintenance of the animals.
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E. CCAC Compliance and The Animal Care Committee 
The CCAC works closely with insitutional animal care 
committees. These committees, which include a community 
representative, are responsible for the welfare of research 
animal s bef ore, after and during experimentation, and are 
accountable to the CCAC. The ir purpose is to en sure that 
optimal conditions of animal care are maintained and that 
6 
there is compliance with the guidelines. They meet regularly 
to review all research protocols involving animals, survey the 
animal housing facilities, ensure compliance, and heJp 
ressolve problems which may arise. Each experiment must be 
approved as ethically acceptable before it can begin and the 
commi ttees can stop an experiment which devia tes from a 
protocol, violates the guidelines, or causes an animal pain or 
distress. 
The CCAC Guidelines are now enforceable 1n the prov1nces of 
Nova Scotia and Prince Edward Island through legislation 
enacted during the 1990's and more fully described in the 
following section. 
F. Provincial Legislation 
i. Prince Edward Island 
The P. E. I. Animal Health & . ]? ' d Protect1on Act - prov1 es that 
regulations may be made by the Lieutenant Governor in Council 
respecting the use of animals for the purposes of medical or 
scientific research. The regulations issued 13 provide that 
the standard of care to be applied with regard to animals used 
in medical or scientific research shall be those contained in 
the Guide to the Care and Use of Experimental Animals 
published by the CCAC. 
11. Nova Scotia 
The Nova Scotia Animal Cruelty Prevention Act penalizes those 
who cause animals unnecessary pain or distress 14 and 
empowers the Governor General in Council to make regulations 
prescribing the facilities, standard of care and euthenasia 
practices for animals kept for research purposes. 15 However, 
a research project may be exempted from these regulations 
where it is "conducted persuant to an audit program approved 
by the Canadian Council on Animal Care". 16 
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iii. Ontario 
Ontario has a specifie Animals for Research .~ct 
li' which 
provides for the registration and licensing of research 
facilities. It also makes the c reation of an animal c a re 
committee mandatary and imposes the responsibility on it of 
reviewing the care of and facilities for the animals, as we]J 
as the training and quality of personnel, and the procedures 
for the prevention of unnecessary pain to the animais. The 
research project proposai must be submitted to the committee 
with a description of the procedures, the number and type of 
animals to be used, and the pain level of the procedures. The 
Animal Care Committee has the power to suspend any procedures 
and arder the euthenasia of any animal suffering pain or 
illness which cannat be alleviated. Although the CCAC is not 
mentioned directly, its Regulations have been copied into the 
legislation. 
1v. Manitoba 
The Manitoba Animal Care Act 18 qualifies the use of animals 
for research and teaching as an "accepted activity".
19 It 
also provides that the research must be carried out 1n a 
manner consistent with regulations, and with generally 
accepted practices or procedures and not cause needless 
ff . 20 lth h 1 . . f. 11 su er1ng. A oug CCAC Regu at1ons are not spec1 1ca y 
mentioned, it is reasonable to believe that their application 
would be enforceable given this legislative provision. 
3. THE PIG AS ANIMAL OF CHOICE 
A. The Pig in Xenotransplantation 
Miniature swine are the preferred subjects in rouch animal 
research. They are desirable to researchers because their 
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mature weight is about the same as that of man, and their 
heart and circulatory system, diet, alimentary tract, skin, 
and teeth are very similar to those of a human. They develop 
stomach ulcers and cardiovascular diseases ressembling those 
of humans. They have been used 1n research on heart and 
va seul ar disease, diabetes, dentistry, nutrition, oncology and 
renal physiology. 
Pigs are also the animal of choice as organ donors as they are 
more amenable to specifie pathogen free colonies, requ1re 
shorter generation time, and can be genetically manipulated to 
deal with hyperacute organ rejection. 21 It is felt that any 
adverse effects which might be incurred by the pig in 
supplying organs for xenotransplantation would not outweigh 
the potential benefits to humans. 22 23 
The pig is also acceptable by community standards. Our 
society has no problem accepting the breeding of pigs for 
food, footballs and clothing, and therefore should not have a 
problem accepting their breeding to save human life. 
Moreover, although they are intelligent and sociable animais, 
they do not appear to share other capacities with humans as do 
primates. Most would agree that: 
"In the final analysis, a pig 1s still a four legged 
animal with a snolet that forages for food, and, given 
the opportunity will eat itself to death." 24 
Severa! different strains of swine have now been developed for 
use in medical research. To ensure that the conditions under 
which they are bred and reared are of maximum standards and 
that any pain and suffering is kept to a minimum the CCAC 
guidelines specifically applicable to swine provide criteria 
for their housing, maintenance and nutrition, group size, as 
well as instructions as to their handling in the experimental 
situation. However, the question of genetic manipulation is 
not addressed. 
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B. Genetic Manipulation - The Frontier against Rejection 
The genetic manipulation of the p1g to prepare it as an organ 
donor presents problems not only to the scientist but to 
animal rights advocates as weil. In order to understand the 
reasons for the gene modification it 1s necessary to 
understand the process of organ rejection. 
Through its immune system, the human body rejects foreign 
abjects. This includes transplanted organs, wi th obvious 
disastrous results. Four types of rejection mechanism have 
been documented, namely, hyperacute, acute vascular, acute 
25 
cellular and chronic rejection. Hyperacute rejection 
occurs immediately or within minutes of the transplant and is 
the biggest problem with xenotransplantation. 
Hyperacute rejection 1s an antibody response. This 1s 
triggered by the white blood cells of the recipient which 
produce antibodies which bind to molecules (antigens) found on 
the surface of transplanted organs. When the antibodies in the 
recipient bind to the antigens on the foreign organ, a 
complicated reaction, called the complement reaction, occurs. 
Complement is a system of over twenty different types of 
protein. As soon as the blood flow is established with the 
transplanted organ, complement becomes activated and destroys 
the cells of the transplanted organ. Complement is prevented 
from attacking the body's own cells by complement regulating 
proteins carried on the surface of the cells. When these are 
not present, hyperacute rejection will take place. These 
regulators of complement activity are species specifie. 
Therefore human regulators regulate human complement, and pig 
regulators regulate pig complement. Consequently scientists 
are attempting to find a way of expressing human regulators in 
pig cells in order to render them resistant tb hyperacute 
rejection. 
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The other forms of rejection occur when cells and antibodies 
of the host attack the foreign cell s of the t.ransplanted 
organ. Acute vascular rejection occurs with allotransplants 
when the attack on the transplanted organ adds to blood 
clotting and inflamation thereby promoting rejection. With 
acute cellular rejection which also occurs with 
allotransplants, particular white cells, known as T-cells, 
directly attack the cells of the transplanted organ and kill 
them. Immunosuppressive drugs are used to control this 
reaction. In arder to minimize this reaction, an attempt is 
made to match the antigens of the donor and recipient, and the 
recipient receives immunosuppressive drugs which may reduce T-
cell activity, reduce the number of T-cells or inhibit the 
production of antibodies. However it would appear that this 
T-cell attack 1s stronger with xenotransplantation and 
consequently stronger drugs would be necessary. 26 Chronic 
rejection can occur months or years after an allotransplant 
and the underlying mechanisms are not yet understood. 
Having settled on the pig as donor, we face the problem of 
preventing rejection. How is the warfare of the cells to be 
prevented? As mentioned above, one way is by expressing human 
regulators in pig cells in arder to render them resistant to 
hyperacute rejection. One method of doing this is by the 
genetic modification of the proteins that sit on the cells so 
that the attacking deviees are not activated. A fertilized 
egg is removed from the sow, between one and three specifie 
human genes are inserted into the egg cells in vitro, and the 
eggs are reimplanted. The blood vessels of the resul ting 
piglets contain human molecules that can turn off the initial 
immune attack. In other words, pig organs are partially 
modified and disguised to look like those of a human at least 
to the immune system. In a small percentage of the animals, 
this transgene will be incorporated into the pig's genetic 
material and transmitted to future generations through 
appropriate breeding techniques. The donor pig will then fall 
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into that class of animals known as transgenic. Such animals 
have now been produced for almost fifteen years and the 
process is well established and painless. Furthermore, the 
procedure does not appear to harm the p1g 1n any way; it 
continues to look and act like a p1g. 
It has been reported that experimentati o n 1s currently being 
carried out giving the organ recipient an injection of pig 
bone-marrow cells so that the animal's immune ce lls will be 
produced . It is hoped that the patient will end up with a 
combined 1mmune system. The re 1s concern, however, that 
retroviruses will integrate their own genetic material into 
the cell s of the human. If such v1rus infects the egg or 
sperm cells, the pathogen ca n pass undetected from one 
'>7 generation to the next. ~ 
C. The Risks of Genetic Man ipulation 
A gene by itself, has no specifie spec1es characteristics. 
The genome consists of a totality of genes operating and 
interacting together . It is far from a single isolated gene 
which makes a human, human, or a pig a pig. Non modified pig 
fetal cells have been transplanted into patients with 
Parkinsons Disease; this has not transformed them into pigs . 
There are between 50,000 and 100,000 genes which constitute 
the pig genome and to this will be added one to three of human 
or1g1n . The effect is minimal and specifie; that is, to vary 
surface antigens thereby neutralising the rejection process . 
The pig ' s characteristics and appearance wi 11 rema1n 
unchanged. It is understood that the pig must not suffer, its 
welfare and rights are to be upheld and controled , and it must 
be monitored for any possible adverse effects . Furthermore, 
permitting a specifie genetic modification, does not mean that 
all others are also to be allowed automatically and without 
objection . Control must be of paramount importance . 
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It 1s argued that the physiological effect of the genetic 
modification of the pig in arder to render it a more ef f icient 
organ donor, lS largely unknown. Similarly, the effect of 
such modification on possibl e pathogenic microorganisms within 
the donor animal or on their potential transfer to the human 
recipient is also largely unknown, and consitutes o ne of the 
major problems with regard to xenograpbic tra nsplantation . 
Regulation is necessary in arder to avoid abuse such as t hat 
which occurred in the creation of Pig No . 6707, the pig with 
the human growth gene implanted 1n its genome. Supposed to be 
a super pig, No. 6707 turned out to be an excessive ly hairy, 
lethargie, arthritic, impotent, slightly cross -eyed animal 
which could barely stand; "the wretched product of a science 
. h h . 18 w1t out et 1cs". -
The ability to manipulate genes is tantamount to the power to 
tinker with nature and change the course o f evolution itself. 
The creation of transgenic anima 1 s can be helpful 1 n the 
treatment of human disease, but it can also be environmentally 
hazardous, dangerous to public health and cruel to animais. 
The creation of mice with the human AIDS virus implanted in 
the ir genome, resul ted 1n a generation of very sic k m1ce. 
This may have provided an instrument for the study of AIDS, 
but at what r isk to the public and at what pr 1ce to the 
29 JO animal. These dangers were subsequently confirmed 
thereby vindicating the fear and concern which had been 
expressed regarding this experimentation and the use made of 
this new technology which had made it possible . 
4. THE NON HUMAN PRIMATE AS DONOR 
An obvious question arising from the choice of the pig as 
donor animal 1s, why not use the non human primate instead? 
It is known that the more closely related the species, the 
weaker will be the 1mmune response. It would appear, 
therefore, that it would make sense to use primates as the 
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donor animal. However, primates are complex animals at the 
high end of the scale with regard to t heir capacity to suffer , 
self awareness, mental capacity and social interactions. It 
lS al so diff icul t to rear them ln capt iv i ty, they breed 
slowly, and their greater similarity to humans a lso in c reases 
the likelibood of cross -specles disease. Bec ause they must be 
free of disease, wild animals cannat be used and breeding 
animals free from infectious organlsms requlres Cesarian 
birth, repeated monitoring and isolation, a ll of which would 
be stressful for primates because o f their intelligence an d 
social nature. Moreover, their similarity to humans makes 
their use feel wrong o r unethical. There are those, however , 
who feel it would be wrong to fail to save a human ]ife even 
if the priee o f so doing was the sacrifice o f a primate ] ife . 
Given the greater risk as well as the practical difficulties, 
the mora l dilemma, and the natural repugnance of harvesting 
organs from an animal whi c h so ressembles humans, the use of 
primates as donors is minimal and remains unregulated largely 
on the irrational grounds that because they are not, in fact, 
being used, it is unnecessary to regulate their use. 
In summary, the scientific community has concluded that the 
practical problems are too great and the rights of primates 
are too strong to justify using them in this research, unless 
there were no other way of obtaining crucial information. 
However the use of the pig is considered acceptable 
31 
and 
is justified by comparing the harm to the pig as donor with 
the harm to the recipient if the re lS no donor. It lS 
worthwhile considering, however, whether primates will have to 
be considered as experimental recipients before 
xenotransplantation is attempted with human subjects . 
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5. THE ETHICS OF ANIMAL USE 
A. Animal Rights - Human Obligations 
To every right there 1s a corresponding ohligation, which, 
sanctioned by law, gives meaning to th e term social arder. 
The rights of animals ca n only be defined through the 
obligations of humans towards them . Th e l a ws which protec t 
animals do so by imposing rules upon man. Such rules address 
our obligation to treat them and care for them in a humane 
fashion; our obligation to refrain from inflicting pa1n and 
discomfort upon them unless absolutely necessary, our 
obligation to refrain from using them unnecessarily and our 
obligation, when we end their lives, to do so pain]essly. 
Animals do not have the capacity to speak for themselves, and 
legal sanctions must be applied against humans who violate the 
rules. Such sanctions are contained in the law and applied by 
the community. However, humans are divided in their opi nions 
as to what the rights of animals should be and what 
obligations imposed on humans to uphold those rights. 
B. The Ethics of Genetic Manipulation 
1. Ethical Questions 
Although, we have seen that it is consid e red normal for higher 
forms of life to use lower forms in maintaining and nourishing 
themselves, as expermentation involving the genetic 
manipulation of animals continues, there are those who believe 
it constitutes a "unique and unprecedented assault on t heir 
dignity and biological integrity." 32 Th e essence that makes 
a human a human 1s ln his genes, as it is with the p1g. Once 
we have played wi th an animal' s geneti c make-up, does he 
remain that animal? or lB the integrity of his very nature 
compromised? Or lS this any different at all from normal 
breeding practices? After all, a pig has the right to live 
and die as a pig. 
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ll. Religious Opinion 
The Working Party of the Nufield Council on Bioethics was set 
up in the United Kingdom in 1995 when Imutran Ltd. foresaw the 
first xenografts of transgenic plg hearts int_o humans as 
taking place in 1996. It engaged in wide public consultation 
of Universities, religious bodies, professional colleges and 
organizations, animal welfare organizations, health and 
research institutes, ethics groups, scientific organisations 
and individuals and published its report ln 1996. 33 Among 
the submissions received was one by the Jain Academy saying 
that Jains are against all animal experimentation and use of 
animal tissues, cells and organs, as it is against all the 
34 principles of reverence for life and non-violence. The 
submission of the Union of Muslim organizations states that 
xenografts might be allowed so long as the animal was not a 
pig or other prohibited anima1. 35 The medical ethics group 
of the Reform Synagogues of Great Britain stated that the duty 
to humans outweighs that to animal s so long as 
possible is done to prevent animal suffering. 36 
everything 
The Church 
o f Wales, in its submission, regards transgenic techniques as 
an extension of traditional breeding techniques that 
artificially produce new animal breeds. 37 The Church of 
Scotland felt that eating animais was natural, whereas using 
38 their organs as spare parts, was not. 
iii. Traditional Thought 
In traditional European thought, the animal lS considered an 
object. In the Bible only man is created in the image of God. 
To Aristotle, what differentiated man from an animal was his 
rationality, and in the natural order the lesser is made for 
the use of the greater. 
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Thomas Aquinas observed that humans use animais and anima ls 
use plants. From this he deduced that to kill an animal for 
food or clothing 1s not a s1n. There must be no cruel ty 
towards animais because this can lead to crue] ty against 
humans. Otherwise there 1s no charity exte nd ed towards non 
rational animais . 
To Descartes, body and soul are distinct. Thought and f eeling 
be long to the immorta 1 soul; the body 1s but a machine . 
Because animais don't talk they have no soul , feel nothing and 
do not benefit from spiritual life after death. Only humans 
combine body and soul . The right o f man to exploit animais 
1s justified because animais have no i~mortal soul. Therefore 
if we also do not have a soul then our treatment of animais 
cannat be justified as we are no different from them . 
However, if they do have a soul, then we are alike and our 
treatment of them aga in cannat be just if ied. To justify 
Cartesian philisophy, animais must be thought of as Lools . 
They are, nonethless, to be accorded humanita rian treatment. 
Utilitarianism prevailed in the mid 18th century, and it was 
sensation and sentiment which were accepted as the basis of 
moral consideration . The virtuous act was that which gave the 
greatest pleasure to the recipient. Since animais were 
considered to be sensible beings, cruelty towards them was not 
acceptable and to brutalise them was reprehensible for t he 
utilitarian reason that it diminished their well being .. The 
question was not can they speak, or can they reason, but can 
they suffer. 
1v. Contemporary Thought 
Humanitarian treatment of animais 1s advocated, and 
legislated. The rights of animais tend to be seen 1n the 
context of biological equilibrium . Consequently, they can be 
sacrificed to maintain that equilibrium, that is, eaten, and 
for experimentation. 
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These ideas are reflected in the object ives of the Frenc h 
39 Animal Rights League whose objectives flow from the 
prem1se that the human rac e shares the same origins as other 
animal species and consequently humans and other spec ies have 
an equal right to existence on earth. It follows from this 
that the characteristics unique to the human ra c e do no t g1v e 
humans the prerogative to ownership over all forms of lif e . 
This argument lS further elaborated 1n chapter 5, "The 
Patenting of Living Matter." 
v. Theory of Equal Consideration of Interest. 
An equal consideration of interest to all 1 i ving things 
capable of suffering does not mean identical treatment, but 
rather that the interests of each shall count equally. It is 
the capacity to suffer that gives an animal the right to equal 
consideration of its interests. The interests of the human 
should not weigh more than the interests of another animal; 
specism must be eradicated. 
Prior to the animal liberation movement of the 1970s animals 
remained lower creatures worthy of protection only when human 
interests were not at stake. Human beings were seen as 
distinct from and superior to all forms of animal life. The 
liberationists wanted to extend basic moral ideas of equality 
and rights which are applied to humans, to animals as well . 
The equality is equal consideration of interests; i.e. the 
animal ' s pain matters as muchas human pa1n . 
The anti-specist philosopy 1s well articulated by Peter 
Singer. 40 We distanced ourselves from animals by thinking 
only we are created in the image of God, only we have souls . 
However this cannot be scientifically proven . The belief that 
all humans are more valuable than animals is a prejudice, no 
different than racism or sexism . We can no longer regard the 
planet as a ressource to be plundered for immediate human 
needs . 
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Singer continues the exposition of his theory by asking why we 
would not take the heart from a cortically dead or 
anencephalic infant to save another infant with a non 
survivable heart rather than have them bath die. He then 
compares the sacrifice of one such infant for its organs with 
the sacrifice of a baboon and queries whether it lS 
justifiable to prefer the interests of our own specles. He 
concludes that speciesism lS a reflection of our power over 
other animais and our lack of consideration of their 
interests. He refers to our society as one which accepts the 
rearing of pigs in miserable conditions in intensive farms, 
and then allows them to be killed just because sorne people 
prefer pork to tofu, and concludes that just because humans 
rear animais to satisfy their tastes does not mean it ls 
right. 
"If anyone thinks that it lS wrong to attempt to use the 
body parts of animais for transplantation purposes, but 
alright to use them for breakfast, then their way of 
h 0 k 0 h h 0 ° 0 h 0 " 41 t ln lng as not lng ln common wlt mlne. 
"In a better world, a world that cared properly for the 
interests of animais, we would do our utmost to avoid 
choices that pit the essential interests of animais 
against our own, so that the issue of the child or the 
baboon does not arise. This might involve more effective 
ways of obtaining organs from humans who are brain dead, 
or cortically dead. It might involve the development of 
artificial organs. Or it might involve using our limited 
medical resources to educate people in looking after the 
organs with which they were born. These are ethically 
preferable paths to pursue." 42 
This philosophy accepts the use of animais for research but 
only if the experimenter would also use a new born baby, 
senile person or severely handicapped person. Otherwise we 
have specism. 
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6. CONCLUSION 
It lS research which has enabled man to benefit from suc h 
everyday treatments as insulin and the pacemaker, and our law, 
in conformity with The Declaration of Helsinki, provides that 
biomedical research involving humans should be preceeded by 
animal experimentation . 43 However, public opinion is divided 
between those who believe that the use of animais in research 
cannat be morally justified as all subjects of life are of 
equal value and humans have a duty to act with respect for the 
inherent value of life, and those who are of the opinion that 
their use in research is justified so long as the researcher 
acts ethically by using the minimum number, by caring for them 
properly and by avoiding or minimizing their pa1n and 
suffering . Still ethers, such as Peter Singer, would agree to 
their use only on condition that humans on the same 
intellectual and emotional level be used as well . 
If xenotransplantation 1s to become acceptable within our 
society, these opinions must be openly discussed and debated . 
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CHAPTER 3 - THE HUMAN AS RESEARCH SUBJECT 
Mu ch experimentation remalns to be do ne be fore 
xenotransplantation can become an accepted treatment. Among 
the experiments necessary will be those using human subjects. 
Where scientific research involves experimentation with 
humans, bath the experimental procedure and the researcher are 
subject to a variety of laws and regulations. Th e physician 
remalns the protector of the life and health of his patient, 
now a research subject, but his goal is to test an hypothesis 
thereby contr ibuting toward the accumulation of sci e nt if :ic 
knowledge. He must act in accordance with existing laws and 
guidelines. 
1. DECLARATIONS OF PRINCIPLE 
A. The Nuremberg Code 
Many of the physicians who carried out experiments ln the 
concentration camps during World War 11 were eventually tried 
ln 194 7, ln Nuremberg, Germany, and the American judges 
formulated a document which became known as the Nuremberg 
Code. 1 
This "doctors trial" was a murder trial for crlmes against 
humanity. The accused, as physicians, had taken the 
Hippocratic oath to do no harm, and the Tribunal questioned 
the adequacy of Hippocratic moral ideals to protect human 
research subjects. It also looked at the Hippocratic 
commandments as they applied to the physician, and to the 
researcher. The assumption was that the physician would act 
in the best interests of his patient, but that the reseacher's 
goal was to test a scientific hypothesis according to a 
protocol. In other words the beneficent context of the 
patient-physician relationship was no longer there to protect 
the patient as research subject. 
The Nuremberg Code consists of ten principles which grew out 
2 
of the actual trial . It empowers the subject by requ1r1ng his 
free and knowledgeable consent a nd by permitt.ing him to 
withdraw from the project at any time, and it protects him 
against unqualified researchers, unjustified risk and 
unnecessary suffering. Al though never adopted as law, the 
provisions of the Nuremberg Code serve as a model for other 
guidelines including the current United States federal 
research regulations. 
B. The Declaration of Helsinki 2 
Whereas the Nuremberg Code emphasises the rights of human 
research subjects, the Declaration of Helsinki sets out the 
obligations of researchers towards them. First adopted by the 
18th World Medical Assembly at Helsinki, Finland, 1n June 
1964. this document contains 1n its Introduction a statement 
of the ''mission" of the physician to safeguard the health of 
"the people", and to act only in the patient's interest . It 
recognizes that "Medical progress is based on research which 
ul timately must rest 1n part on experimentation invol ving 
human subjects." It provides that the purpose of such research 
"must be to improve diagnostic, therapeutic and prophylactic 
procedures and the understanding of the aetiology and 
pathogenesis of disease." It provides that research using 
human subjects be carried out by qualified persans, conform to 
generally accepted scientific principles and be preceded by 
laboratory research and research on animals. It also calls 
for special caution where the environment may be affected and 
a respect for the welfare of animals used for research. 
To protect human subjects, the Declaration stipulates, as 
prerequisites for research, a scientific protocol, committee 
review, proportionality of risk over importance and risk over 
benefit, confidentiality, volunteerism with regard to 
participation and withdrawal, and enlightened consent. It 
also contains a provision that every protocol must state 
specifically that it conforms with the principles enunciated 
in the Declaration of Helsinki. 3 
c. 
4 The Belmont Report 
3 
On July 12, 1974 the U. S . National Researc h Act became law 
creating the National Commission for t he Protection of Human 
Subjects of Biomedi ca l and Behavio ral Research which was to 
identify basic ethical principles that should underlie the 
c onduct of biomedical and behavioral research us1ng human 
subjects, and develop guidelines to insure that such research 
was carried out in accordance with those principles . The 
result was the Belmont Report produced in February 1976. 
The object ive was to provide an analytical frame work to guide 
the resolution of ethical problems ar1s1ng from research 
involving human subjects. The Report held that three basic 
ethical principles, namely, Respect for persons, Beneficence, 
and Justice, provided the basis for "those general judgments 
that serve as a basic justification for the many particular 
ethical prescriptions and evaluations of human actions". 
1. Respect for Persons 
Respect for persons g1ves r1se to the principle of Autonomy as 
manifested by free and voluntary consent . In order to obtain 
such consent, the investigator must provide the subject with 
all information necessary to make his choice in a form that 
can be understood by the subject and without exerting any 
coercion or undue influence. He must explain, in detail, the 
purpose of the project, the procedures, the risks and benefits 
to be expected, the availability of alternative procedures, 
the fact that the subject can withdraw at any time, and a 
contact person for further information. Wi th 
xenotransplantation, many people may be affected, even whole 
populations. The consent of the beneficiary al one may no 
longer suffice, and the necessity of obtaining the consent of 
third parties as well, will be discussed 1n the following 
chapter. 
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ii. Beneficence 
This translates into an obligation to do no harm, to mlnlmlze 
risk and to maximize benefits. However, 1n research, what 1s 
harmful 1s often unknown and therefore the subjec t ma y be 
exposed to risk. It is here that the possible ben e fits must 
be balanced against possible risk . Beth the probability and 
magnitude of the risk must be assessed, and the recipient of 
the benefit, namely, the subject himself, a group, or society 
as a whole, must be specified. The subject must be protected 
from risk of harm while ensuring that society does not Jose 
the possible benefits to be gained from the research. In the 
case of xenotransplantation it will become necessary to 
recognize that the risk may be borne not only by the recipient 
but by those with whom he cornes in contact and possihly by 
society as whole. In this case it is society which must be 
protected from risk of harm while ensuring that the individual 
does not lese the possible benefit to be gained from the 
research. Only where the risk \ benefit ratio is favourable 
will the research be justifiable, and the measurement will 
change. The customary assessment of risk to subject as 
against possible long term benefit to public, reverses to one 
of benefit to subject as against long term risk to public. 
111 Justice 
This 1s also referred to as distributive fairness. He who 
benefits from the research should be the one to undergo the 
risk. The history of injustice in this a rea is flagrant; 
wi tness the Tuskegee (Alabama) syphi 1 is studies 1n which 
prisoners were infected and then remained untreated even when 
treatment became available so that ethers could benefit from 
the knowledge obtained. The final report on this study was 
produced as recently as 197 3. 5 Toda y, this would not be 
permitted, and the Belmont Report 6 provides that the 
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selection of subjects be fair. It specifically prohibits 
researchers fom offering potentially beneficia} research only 
to patients in their favour and from selecting "undesirable" 
persans for risky research. It further provides that 
prisoners as well as the institutionalized mentally infirm can 
only be subjects of experimentation under special conditions, 
if at all. 
Prisoners receive protection in the U.S.A. under the American 
Code of Federal Regulations 7 , as well as under the U.S. Food 
8 
and Drug Regulations Canadian 
different. The Law Reform Commission 
to equal sharing of benefits and 
op1n1on lS somewhat 
9
, while it subscribes 
inconvenience 10 and 
questions the quality of the consent of which a prisoner can 
11 be capable, , it also values the argument which states that 
the peremptory exclusion of prisoners as subjects 1s 
discriminatory and un just. 12 It concl udes, however, that 
more thought is required before it can take a stand on the 
issue. 13 
The question of subject and patient criteria continues to 
remain a medical and ethical issue today, for example with 
regard to the social and psychological suitablity of organ 
transplant recipients. However, the main problem at this time 
1s funding and availability. The need and desire for 
treatment have become the prime motivating factors in turning 
patients into subjects. A patient in dire need of an organ 
transplant in arder to live becomes a ready subject when the 
alternative is certain and almost immediate death. Under these 
circumstances, distributive fairness takes on a different 
meaning. The individual may benefit, but at what risk to the 
public? 
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2. UNITED STATES LAW AND REGULATIONS 
A. The Health Research Extension Act of .1985 
14 
This American Act provides, that every entity applying for a 
grant under the Act for biomedical research involving human 
subjects, must establish an Institutional Review Board (IRB) 
to review the research "in arder to protect the rights of the 
human subjects of such research". This law is implemented by 
. d 1 . 1 t ' 15 the Code of Fe . era ~egu a lons. 
B. Code of Federal Regulations, 45 CFR 46 16 
These regulations, issued by the United States Department of 
· Health and Human . Services, the National Institute of Health, 
and the Office for Protection from Research Risks, set out 
American public ~olicy for the protection of human research 
subjects. They apply to such research conducted, supported or 
·subject to regulàtion by any federal department or agenc:y. 
They define "research" as "a systematic investigation, 
... designed to develop or contribute to generalizable 11 knowledge." Funding depends on compliance with the 
regulations and anyone who appl ies for money must assure 
compliance. 18 The - regulations require that the Institution 
provide an assurance to the funding agency that it will 
protect the rights and welfare of human subjects, and 
stipula te detailed rules for . the IRB review procedure. 19 
The criteria for IRB research approval are set .out in detail 
'and include aisessment 6f risk, equitable selection of 
research subjects, obtaining 
monitoring and ~rotection of 
required content of the consent 
of informed consent, data 
subject privacy. 20 The 
is also set out in detail.~] 
C. ~rican}Food and Drug Administration Regulations. 22 
All clinical investigations regulated by the Food and Drug 
Administration must conform to these regulations entitled 
"Protection of Human Subjects". "Clinical investigation" is 
7 
defined as "any experiment that involves a test arti c le and 
one or more human subjects .. . ", 23 and ''Institutional review 
board " (IRB) as "any board, committee, or other group forma] ly 
designated by an institution to review biomedical research 
? ' 
involving humans as subjects .•. " ~ 4 
1. Consent 
The Regulations provide that no human being may be involved in 
research unless the investigator h as obtained "the legally 
effective informed consent of the subject ... " 25 Possibility 
of coercion and undue inf 1 uence must be minimized and the 
subject must have suffcient opportunity to consider wh ether or 
not to participate . 26 Information given the subject "shall 
be in language understandable to the subject or the 
?~ representative."~~ The nature and purposes of the research 
must be explained as well as a description of the procedures . 
Also provided for lS "a description of any reasonably 
foreseeable risks or discomforts to the subject", 28 and a 
description of benefits to the subject or to ethers which may 
reasonably be expected from the research . 29 Alternative 
procedures or treatments advantageous to the subject must be 
disclosed . 30 Details regarding confidentiality, compensation 
in the event of in jury, vol untary participation, contact 
persans, risks, possibility of withdrawal without penalty, 
must be included in the consent form. 31 The written consent 
3? lS to be IRB approved . -
ii Protocols 
Protocols must be reviewed and approved by an IRB 33 and they 
rema1n subject to continuing review. For approval the 
following criteria must be met: 
1. Risk must be minimized 
2. Risk must be reasonable ln relation to anticipated 
benefits, and importance of knowledge that may be expected to 
result. 
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3. Selection of subjects must be equitable. 
4. A proper consent form must be signed 
5. Data must be validly monitored 
6. Privacy of subjects is to be protected as much ~s possible 
7. The rights of the disadvantaged and vulnerahle must be 
34 protected. 
The regulations provide for use of a drug that is not approved 
for marketing but 1s "under clinical investigation for a 
serious or immediately life-threatening disease condition in 
patients for whom no comparable or satisfactory a lternative 
drug or ether therapy 1s available." 
35 This f ac ilitates 
availability to desparately ill patients early in the drug 
development process. It is well to not e l hat permission may 
be denied "if there is insufficient evidence of safety and 
effectiveness to support such use," or if there 1s no 
reasonable basis for concluding the drug may be effective for 
i ts intended use, or would not expose the patient to an 
unreasonable and significant additional risk of illness or 36 
injury. There must be informed consent and IRB approval . 
These provisions help bridge the gap between the time a 
procedure is experimental, and consequently must be regulated 
as such, and the time it can be accepted as therapy . 
Sometimes the gap can be closed qui c kly as happened when 
cyclosporine was found to be useful as an antirejection drug 
in 1978. 37 The success rate for kidney transplants went from 
45 % to 50 % to 80%; that for heart tranplants from 45 % to 80 %, 
and that for liver transplants, from 35 % to 75 %. 
38 
Should a drug suddenly appear with similar results in the case 
of xenotransplantation , permission for use could be 
expedi tiously obtained , patients awai ting organs could bene fit 
from the procedure early into the experimental stage and the 
characterization of xenotransplantation might rapidly be 
changed from experimental to therapeutic . This would be 
predicated on there being no reasonable basis for concluding 
9 
that the patient or third persans might be exposed t o an 
"unreasonable and significant additional risk of illness o r 
injury." 
Other sections of the Regulations provide "procedures designed 
to expedite the development, evaluation, and marketing of new 
therapies intended to treat persans with life -threat e ning and 
severely-debilitating illnesses, especially where no 
satisfactory alternative therapy exists ." 39 Although a 
satisfactory risk-benefit ratio, consent and IRB approval are 
all required, the members of the IRB would not, at least at 
this stage of our knowledge, have available to them sufficient 
information to consider the issues involved, and the risk-
benefit assessment would require a mind set totally different 
from that to which we have been accustomed to dat e . 
Fortunately, the U.S. Public Health Service appears to be very 
aware of the differences and difficulty of the issues involved 
and has recently produced a set o f draft regulations 
applicable to xenotransplantation. 
D. 
40 
Draft Guidelines on Xenotransplantation 
Clinical investigations of xenograft products including whole 
organs are subject to investigational new drug regulations 
41 
under the Food and Drug Act. This includes investigational 
42 
new drug regulations 
regulations 43 , and informed 
Institutional Review Board 
. 44 
consent regulatlons . Among 
the examples of such ongoing research was the use of porclne 
livers as a 
1 . 45 transp antatlon. 
temporary 
Although 
infection of humans exist, 
bridge 
examples 
there were 
to 
of 
no 
human organ 
trans -species 
guidel ines for 
adequate screening of donor animal cells, tissues, and organs, 
intended for human transplant or recommendations for post-
transplantation patient monitoring. 46 
In 1994 several IRB committees expressed concern regarding the 
source and characterization of donor animal tissue
47
. At the 
same time, the Secretary of Health requested that agencies 
10 
reach a consensus on the infectious disease risks and safety 
1ssues raised by xenotransplantation. 48 Several agency 
meetings and public forums were held in 1995 at which the 
projected guidelines were discussed, and several scientific as 
well as lay reports were submitted. 49 The Institute of 
Medicine (IOM) held a study and public workshop resulting in 
a report released July 17, 1996, the IOM Report, which 
recommended that national guidelines be established for all 
experimente~s and institutions that undertake 
xenotranspla~tation trials in humans. 50 
The purpose 1of these guidelines is "To discuss public health 
issues relat~d to xenotransplantation and recommend procedures 
to diminish the risk of transmission of infectious agents to 
the recipient and the general public. 51 " It is an attempt 
to "strike a balance between the public health risks and the 
potential promise of xenotransplantation .•• ". 52 
These guidelines recogn1ze 
increasing importance of 
xenotransplantation as "an 
approach", as well as the 
the need for organs and the 
research 1n the area 
investigational therapeutic 
need to address public heal th 
issues. They attempt to regulate procurement, screening and 
use of xenografts, clinical care and follow up of recipients 
as well as screening of donors. The draft guidelines are non 
binding and create no rights or obligations. They represent 
current thinking and are meant as a source of information. 
The Regulations set out the scientific concerns and problems: 
a. Lengthy Incubation Pcriods: Retroviruses and pr1ons may 
not produce clinically recognizable disease until many years 
after they enter the host; 
b. Inadequate Diagnostic Technology: Sorne infectious agents 
are not readily detected or identified in tissue samples by 
current diagnostic techniques; 
11 
c . Unknown Risk: The full spectrum of infectious agents 
potentially transmitted via xenograft transplantation is not 
well known; 
d. Differences 1n Species Reaction: Infectious agents that 
produce minimal symptoms in animals may cause severe morbidity 
and mortality in humans; 
e. Commercial Breeding of Source Animals: There is need for 
consistent standards of source animal screening and qual ity 
cont rol. 
Although zoonosis lS a recognized danger, xenotransplantation 
provides more than norma 1 contact or product cons umption; 
there lS a disruption of anatomical barriers as well as 
immunosuppression of the recipient thereby facilitating 
interspecies transmission of xenogeneic infectious agents. If 
undiagnosed, viral infections may be passed on, but lie 
dormant for years before becoming clinically evident, thereby 
allowing an infectious agent to become establ ished 1n the 
general or susceptible population before it is recognized . The 
objective of the guideline 1s " to present measures that can be 
used to minimize the risk to the public of human disease due 
to known zoonoses and emerging xenogeneic infectious agents 
arising from xenotransplantation ." 53 The suggestions as to 
how this is to be done are as follows: 
1. The xenotransplant team must have special expertise ln 
the evaluation of infectious agents in both the donor and 
recipient; 
2. Virology 
capability to 
and microbiology labs 
isolate and identify 
pathogens must be readily available; 
with expertise and 
unusual and unknown 
3. The protocols are to be reviewed by a Biosafety Committee 
with expertise to assess potential risks of infection for the 
contact population and recipient, as well as by an Animal Care 
and Use Committee with expertise to evaluate epidemiological 
concerns related to conditions of source animal husbandry, and 
by an IRB with expertise in human and veterinary infectious 
12 
diseases including virology and laboratory diagnostics, 
epidemiology and risk assessment. 
4. Protocols must include procedures for sceening of 
infectious agents prior to transplantation, and surveillance 
of the recipient and of those with whom he cornes in contact 
following transplantation. 
5. The consent would be based on CFR regulations as well as 
on the principles of the Belmont Report and specify the risk 
of both known and unknown infectious agents, the potential for 
delayed manifestation and transmission to third parties, the 
need for continuing, possibly life-long, evaluation and 
. 54 
surveillance, and consent to autopsy. 
There are detailed provisions for controlling the source of 
·donor animals, the method of breeding them, which includes the 
possibil ity of cloning as a desirable technique, and the 
animal facility itself.
55 Responsibility for the adequacy of 
the screening program rests wi th the xenotransplant team. 
There is a further screening program for individual animals 
prior to donation, at which time they are also quarantined for 
a suggested period of three weeks. 
Recipients are to be monitored for life. Specimens are to be 
taken and archived. Should there be a cl inical episode 
possibly as a result of a xenogeneic infection "post 
transplantation testing of archived biologie spec1mens should 
be conducted in association with an epidemiologie 
investigation to assess potential public health significance 
of the infection." 
56 This would proceed under the 
supervision of "appropriate health authorities". 
To minimize the risk to the public of human disease due to 
known and emerg1ng infectious agents arising from 
xenotransplantation there are provisions for the education of 
close contacts and of health care workers, for surveillance 
programs, for maintaining 
Xenotransplantation Registry, 
. 57 
spec1mens. 
records, for 
and for archives 
a National 
of biologie 
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Because of potential public risk, accountabi 1 i ty to that 
public is necessary and public awareness and understanding are 
essential. To address public heal th issues the re must be 
obligatory guidelines, regulatory oversight, a national 
committe of multi-disc rplinary experts and lay persons to 
exam1ne scientific, social and ethical 1ssues, public 
discussion through conferences, and frequent and publi c 
reassessment of guidel ines. The se can b e adapted wi th the 
development of xenotransplantation as a scientific procedure. 
It is clinical trials which will provide the data required to 
inform and refine the understanding of the risks and benefits 
of xenotransplantation, and the Guidel ines face up to t he 
possible dangers inherent in the xenotransplantation process 
at this time . They do not create law or obligations, they do 
not bind, they are not an endorsement of xenotransplantation 
nor do they constitute a commitment to fund research. Th ey 
. d . f t . d t . 1 58 h h b prov1 e ln orma 1on an sugges lons on y. T ey ave ecorne 
a part of the debate. 
3. BRITISH LAW 
In England the Hea 1 th & Safety at Work Act , the European 
Communities Act, and the Environmental Protection Act with 
regard to Genetically Modified Organisms regulate the breeding 
of transgenic anima 1 s, the marketing of GMOs ( geneticall y 
modified organisms) and the use of premises for work involving 
genetic modification. England advocates the creation of a 
National Standing Committee with national responsibility for 
oversee1ng the development of xenotransplantation. This 
Committee would advise on further research required before 
clinical xenotransplantation trials can begin, set 
requirements to minimize risk of infection in recipients, set 
standards for the breeding and maintaining of source animais, 
set standards and rules for long term surveillance of 
recipients, set training standards 
involved 1n the process, approve 
xenotransplantation will take place, 
for those professionals 
clinical sites where 
establish criteria for 
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those who will be permitted to perform the procedure, approve 
applications to perform clinical trials with human subjects, 
advise the Health Ministers, advise on developments in 
xenotransplantation especially those which may cause public 
concern, advise on consent and confidentiality, monitor the 
psychological effects, and advise on allocation of tissue and 
59 -
organs. 
The Nuffield Council on Bioethics, a British advisory body, 
has discusse~ the necessity of assessing risk, of establishing 
a regulatory mechanism to assure the elimination of infec tious 
organisms from source animal s, monitoring recipients, 
approving ti-ials invol ving human subjects as well as the 
. location of such trials, overseeing the issue of consent, 
assessing the impact on the recipient, and facilitating public 
debate and assessing public attitudes. It has recommended 
that "No xenotransplantation trials involving human recipients 
should proceed until the proposed Advisory Committee on 
Xenotransplantation is in place and the above issues have been 
addressed." 60 
4. CANADIAN LAW AND REGULATION 
A. The Civil Code of Quebec 
Two relevant 1ssues with regard to human subjects in 
experimentation are covered by the Code, namely, r isk and 
consent. 
1. Risk 
Art. 20 C.C.Q. provides that a 
experiment "provided that the 
disproportionate to the benefit 
person 
risk 
that 
may submi t to 
incurred is 
can reasonably 
an 
not 
be 
. anticipated." Neither "risk" nor "benefit" are defined and 
appreciation of the . risk-benefit ratio requires a value 
judgment. Assessment of risk will vary with the nature and 
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gravity of the risk and with the probability of occurence. 
Risk which entails possible death or permanent bodily or 
psychological harm is never acceptable. Benefit c an pertain 
to the individual research subject, to soc iety in genera l or 
to a particular group within that society. 
While our Civil Code remains silent as to the "importance" 
element of the risk equation, the American Federal Regulat i ons 
consider the ratio of risk to importance of knowledg e as we ll 
as the ratio of risk to benefit. 61 In the Ameri ca n sy s t e m, 
not only benefit but the overall importanc e of th e result a nt 
knowledge is to be considered, 
ii. Consent 
Another provision of article 20 C.C.Q. pertains to the 
necessity of consent. Because consent must be freely given, 
all the facts on which it lS based must be known, including 
every detail of any risk, no matter how small or improbable 
its occurance might be. There must be no holding back or 
falsifying of information and undue influence must be avoided. 
Information pertaining to risk must be honest and complete, 
and the subject must have understood. Our courts have 
confirmed that in the case of experimentation, as opposed to 
therapeutic intervention, all risk, no matter how unlikely or 
remote is to be revealed. 62 
The subject cannot consent to what he does not know or 
understand, and at this stage no one can know all the risks 
associated with xenotransplantation. Under these 
circumstances it is obvious that our law Jn Quebec would not 
easily sanction xenotransplantation. 
B. Code de Déontologie des Médecins 03 
The rules which govern the practice of medicine specify that 
the physician must practice the profession in accordance with 
scientific principles64 , in conformity with current medical 
16 
knowledge, 65 and using establ ished procedures. 66 Since 
the physician must always act in the best interests of his 
patient, g1ven the impossibility of assessing risk, 
theoretically, a decision to proceed with xenotransplantation 
would presumably not be possible at the present stage of 
scientific and technological knowledge. However, to the 
individual subject for whom imminent death is a certainty, the 
risk 1s not of the procedure but of death at 100% which 
balances in 1favour of the surgery. The concern is therefore 
one of public and third party safety. 
The Code d~ déontologie des médecins also provides that the 
' 
"free and enl ightened consent" of the subject be obtained 
before any investigation, treatment, or research 1s 
67 
undertaken, and that explanations be gi ven regarding the 
nature, purpose and possible consequences of such 
investigation, treatment or research. 68 Obviously any 
- consent to act as a subject 1n a xenotransplantation protocol 
or to become the recipient of an organ harvested f~om an other 
species donor, would not be validly given, as neither the 
risks nor the consequences are known. The risks in these 
circumstances are not to the subject, but to the community. 
C. Guidelines on Research Involving Human Subjects. 69 
These guidelines were published by the Medical Research 
Council of Canada in 1987 to define the MRC's expectations of 
the research community with regard to research involving human 
subjects. The stated purpose, as found in the Introduction, 
was " ... ta sensitize and guide decision makers on the range of 
perceptions they should bring to bear and to describe the 
processes of decision making that must be observed" when 
making ethical judgments on research proposais. The Guidelines 
apply strictly to research which " •.• is conducted, planned and 
directed toward new knowledge," as opposed to therapy. The 
members of the working group recognized that medical research 
generally inval ves uncertainty and certainly inval ves risk 
which can be del ineated and control led but can ra rely be 
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precisely specified or entirely eliminat e d. The St a nding 
Committee closely followed the Belmont Report and adopted its 
three basic eth ica 1 pr inc ipl es of respec t f o r 1 if e , 
beneficence, and justice. It includes, as well, a dis c u s sion 
on genetic manipulation. 
1. Consent 
A long section lS spent on consent which must be informed, 
voluntary and continuing. Details are sP.t out and the 
Committee states: "The level of dis c losure should be 
proportionate to the likelihood and the scale of possible 
harm, but even the remote possibility of injury shouJd b e 
disclosed. " 70 
ii . Risk and Justice 
"Respect for life both justifies and limits research. As for 
beneficence, mankind may benefit, but individuals place 
themselves at risk. The benefits and risks of research must 
always be weighed. Justice must be exercised in allocating 
the anticipated risks and the hoped-for benefits."
71 
"The eth ica 1 cha 11 en ge th en 1 s to decide ln the 1 ight of 
principle what risks are justifiable and for whom, in relation 
d . "72 to presume ga1n. 
Once aga1n the benefits and risks are being applied to the 
individual subject without consideration of third persons. It 
is in this aspect that xenotransplantation eludes the existing 
legal structure. 
111 Genetic Manipulation 
The Committee had no trouble accepting genetic manipulation, 
stating: "The most likely and practical applications of 
genetic engineering in human beings, closely ressemble well-
accepted medical interventions and provide promising 
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approaches to correct certain well-understood, but currently 
untreatable, genetic deficiency diseases caused by a single 
d f t . . . t . Il 73 e ec 1ve or m1ss1ng pro e1n. 
It was, however r gravely concerned about the ethical 
impl ica tians of germl ine manipulation wh ic h may a 1 ter the 
genetic character of the individuaJ as wel.l as o f future 
offspring, and was not prepared to as rouch as consider such 
genetic engineering in the Guidelines. It also advocated long 
term follow up for the non inheritable cha nges that. are 
current.ly undertaken as routine pract.ice. 
D. Drugs Directorate Guidelines 74 
The Heal th Protection Branch of Heal th and Welfare Canada 
publ ished a set of guidel ines 1n 198 9 on the "Conduct. of 
Clinical Investigations". 
These guidelines which apply to clinical studies of 
investigational drugs, provide that all procedures follow the 
guidelines set out in 1987 by the Medical Research Council of 
Canada. Consent must be obtained and must consist of a "fair 
representation" for which all procedures and tests r 
foreseeable risks and side effects, and possible benefits to 
the subject and to ethers, are to be spelled out stressing 
that the benefits are not assured. The provisions of the 
consent and protocol must be understood by the one signing who 
must be permitted to ask questions and be g1ven time to 
consider. It is even stipulated that the signing should take 
place in the presence of a neutral informed persan and nothing 
contained 1n the document should 1 imi t the investigator' s 
responsibility or abrogate the subject's rights. 
It is interesting to contemplate what would be the nature and 
extent of explanations required to understand the procedure 
and risks of xenotransplantation. 
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E. Medical Deviee Regulations 
· f ft are considered According to Heal th Canada, ~ xenogra s 
therapeutics, then Health Canada has the authority to regulate 
xenotransplantation as a new technology.
75 
Genetically 
· ht 1 b ;ncluded in the modified animal organs m~g a so e • definition of "deviee" under article 2 of the Food and Drugs 
Act. 76 as an: 
"article, instrument, apparatus or contrivance, including any 
component, part or accessory thereof, manufactured, sold or 
represented for use in •.• 
a) the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms, 
in human beings or animals; 
b) restoring, correcting or modifying a body function or the 
body structure of human beings or animals." 
Under the Medical Deviees Regulation 77 an untested deviee 
cannot be sold and the tests must "indicate that the nature of 
the benefits claimed to be obtainable through the use of the deviee and the performance characteristics claimed for the deviee are justified as shown by evidence available ~n 
Canada •.• ". 
To obtain permission to use the deviee for investigational purposes a complete protocol is required together with ethics 
committee approval, written consent, complete data on all 
adverse reactions, and results of previous tests and research. Even where permission is given on compassionate grounds, it 
must appear from the documents, material and information 
available that the benefits that may be obtained by a patient from use of the deviee outweigh the risks associated with its 78 use. 
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under these regulations, as well, · it would appear that 
insufficient knowledge and public risk would prevent the 
granting of permission for use of an animal organ for 
xenotransplantation at the present time. However, with the 
rapid advance of biotechnology, and especially with the 
potential of using animal organs to bridge the waiting period 
for human organ availability, the time has come for public 
education, public discussion, legislation stating what is and 
what is not permitted, and regulation to set the parameters 
for that which is permitted by law. 
F. L'Expérimentation Biomédicale sur l'être Humain 79 
Working Paper 61 of the Law Reform Commission of Canada, 
published in 1989 accepts that new technologies and drugs 
must be tested on human subjects. Thalidomide didn't effect 
monkeys but a generation of children were born handicapped. 
This does not mean experimentation should be prohibited; but 
it does illustrate the necessity for control. 
Among the purposes of the study were assessment of the current 
state of the law, and review of the MRC guidelines to decide 
whether a change in legislation was necessary. 
The Commission accepted the three fundamental principles set 
out in the Belmont Report: namely, respect for the dignity 
and autonomy of the human being from which we derive the 
necessity for free 
reflected in the risk 
obtain the principle 
benefit. 
and informed consent, beneficence as 
benefit ratio, and justice from which we 
of equitable distribution of risk and 
The paper emphasizes the role to be played by the legal system 
in defining the parameters and conditions under which research 
using human subjects can take place, and advocates a joint 
contribution by the legal, medical and ethical disciplines in 
order to ressolve the complexity of problems posed by modern 
biotechnology. 80 
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5. CONCLUSION 
The human, as a subject of research, 1s well protected J_n 
North America by a series of laws, regulations and guidelines. 
The application of sorne of these could probably be broadened 
to include xenotransplantation. The United States Public 
Health Service has now published detailed draft guidelines, 
and an Advisory Committee has been set up by the O.S. Food and 
Drug Administration. Still, we need to pass legislation 
regulating the kind of preclinical data whi c h is necessary, 
the level of risk acceptable and the precautions to be taken 
in order to protect the animals, the huma n s ubjects a nd the 
public, before an ethics committee can allow a research 
protocol on xenotransplantation. The re 1s al so a need to 
extend the application of both existing regulations and those 
of the future to all research with human and animal subjects 
and not just that undertaken or financed by specifie 
institutions. 
A National Forum on Xenotransplantation was held in Ottawa 1n 
November, 1997 as part of the consultation process intended to 
examine the scientific, social, legal and ethical issues 
related to xenotransplantation, and a "Xenotransplantation 
Expert Working Group" has been established to consider 
drafting guide 1 ines and safety standards spec if icall y for 
xenotransplantation. Although xenotransplantation 1s not 
currently prohibited here, no clinical trials have yet been 
approved. However, given the potential ha zards associated 
with the procedure as well as existing law s and regulations, 
it is doubtful that such trials could be approved, at least 
without eliciting a great public outcry. 
Public interest has not been adequately addressed, and ethical 
issues remain unressolved. In the next chapter we will look 
at sorne of these ethical opinions and considerations. 
22 
ENDNOTES TO CHAPTER 3 
1. "Trials of War Criminals before the 
Tribunals under Control Council Law No . 
Government Printing Office, 1949, pp 181 -1 8? 
?\urembe rg 
10 ", vol . 
Military 
2, u.s. 
2. "Wor ld Medical Association Declaration of Helsinki", Adopted by 
the 18th World Medical Assembly Helsinki, Finland , June 1964 and 
amended by the 29th World Medical Assembly Tokyo, Japan, October 
1975, 35th World Medical Assembly Venice, Italy, October 1983 and 
the 41st World Medical Assembly Hong Kong, Septembe r 1989 
3. Declaration of Helsinki, sec. 1 "Basic Pr i nciples " par. 12 
4. "The Belmont Report, Ethical Princ iples and GuidelinPs f or the 
Protection of Human Subjects of Res earch", The Nsat.ional Commission 
for the Protection of Human Subjects of Biomedi ca l and Behavioral 
Research, OPRR Reports, April 18, 1979 
5. "Final Report of Tuskegee Syphili s Study, Ad Hoc Advisory 
Panel", Washington Public Health Services, 1973. 
6. Op.cit, at p. 7 
7. "Code of Federal Regulations", Title 45, Public Welfare, 
Department of Heal th and Human Services, National Institute of 
Heal th, Office for Protection from Researc h Risks, Part 46 
Protection of Human subjects, August 19, 1991, sections 46.304, 
46.305, 46.306, 46.111. 
8. "U.S. Food and Drug Administration Regulations", 21 CFR ch . 1, 
sections 50.42, 50.44, 50.46. 50.48. 
9. "L'expérimentation Biomédicale sur l'Etre Humain", Commission 
de réforme du droit du Canada, Document de t ravail 61, 1989 
10. Op. Cit., page 4 
11. Op. Cit., page 41. 
12. Op Cit., page 43 
13. Op. Cit., page 44 
14. Public Law 99-158, November 20, 1985, sec. 491(a) 
15. Title 45 CFR Part 46 
23 
17. 45 CFR 46, sec. 46.102(d) 
d 1 Regulations, 45 CFR 46, sec. 46.123 18. code of Fe era 
19. Ibid, sec. 46.103 
20. Ibid, sec. 46.111 
21. Ibid, sec. 46.116 
of Hum an Subjects", 21 CFR ch. 1, Psart 22. "Protection 
23. Ibid, 21 CFR ch. 1 , sec. 50.3(c) 
24. Ibid, 21 CFR ch. 1 , sec. 50.3(i) 
50 
25. "Informed Consent of Human Subjects", Ibid, 21 CFR ch. 1, 
Subpart B, sec. 50.20 
26. Ibid, sec. 5û.20 
27. Ibid, sec. 50.20 
28. Ibid, sec. 50.25(2) 
29. Ibid, sec. 50.25(3) 
30. Ibid, sec. 50.25(4) 
31. Ibi~ sec. 50.25(4 - 8) 
32. Ibid, sec. 50.27(al 
33. Ibid, sec. 56.109(a) 
34. Ibid, sec. 58.111 
35. "Treatment Use of an Investigational New Drug'', 21 CFR ch. 1 
sec. 312.34 
36. Ibid, sec. 312.34 
37. Calvin Stiller, Lifegifts, The Real Story of Organ Transplants, Stoddart Publishing Co. Ltd., 1990, p. 24ff 
38. Calvin Stiller, ibid., p. 21 
39. "Drugs intended to Treat Life Threatening and Severely debilitating illnesses", 21 CFR ch. 1, Subpart E, sec. 312.80 
40. "Draft Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation", Department of Health and Human Services, Public Health Service, Docket No.96M-0311, Federal Reg1ster, vol. 61, No. 185, Sept. 23, 1996, p.49919 
24 
41. Ibid. , p.49921 
42. 21 CFR part 312. 
43. 21 CFR part 56. 
44. 21 CFR part 50. 
lth S · Gul·deline on Infectious Disease 45. "Draft Public Hea _ er~1ce Issues in Xenotransplantat1on , op. cit , p 49921. 
46. Ibid, p.49921. 
47. Ibid., p. 49921. 
48. Ibid~ p. 49921. 
49. Ibid. , p. 499:21. 
50. Ibid. , p 49921. 
51. Ib1d, p. 49921 
52. l_pid.' p. 49921. 
53. Ibid. , p. 49922. 
54. lbid., pp 49922 - 49 923. 
55. Ibid., PP 49923 - 49926. 
56. Ibid ., PP 49927, sec. 4.1.1.6. 
57. l.Pid .' pp 49927 - 49929. 
58. Ibid. , p 49921 
59. "Animal Tissue into Humans", A Report by the ~dvisorv Group on the Eth1cs of Xenotrans~lantation, Her Majesty's Statione ry Office, 1996, ch. 9, pp 141-14 • 
60. Nuffield Council on Bioethics, "Animal to Human Transplants, the Ethics o f Xenotransplantation", 1996, p. 122 
61. 45 CFR 46 sec. 46.111(a)(2) 
62. Weiss v Salomon, 1989 R.J.Q. 731, Halushka v The Unive rsity of Saskatchewan, (1965) 53 D.L.R. (2dl 436 
63. c. M-9, r.4 
64. Ibid, secé 2 .03.14 
65. Ibid, sec. 2.03.17 
25 
66. Ibid, sec. 2.03.19 
67. Ibid, sec. 2.03.28 
68. Ibid, sec. 2.03.29 
69. "Guidel ines on Research Invol ving Human Subjects" Medical 
Research Council of Canada, 1987 
70. Ibid, p. 23 
71. Ibid, p. 12 
72. Ibid, p. 13 
73. Ibid, p. 17 
74. "Drugs Directorate Guidelines", Conduct of Clinical Investigations, Health Protection Branch, Health and Welfare Canada, 1989 as amended in 1992. 
75. Heal th Canada, "Xenotransplantation", Informa~_1 o n, Nov. 1997, p. 3. 
76. R.S.C., 1985, c. F-27 
77. CRC c 871, sec. 14 
78. Ibid., sec. 15.1(4)(a) 
79. "L'expérimentation Biomédicale sur l'Etre Humain", Commission de réforme du ~roit du Canada, Document de travail 61, 1989 
80. Ibid., p. 61, ch 4. 
1 
CHAPTER 4 - THE ETHICS OF XENOTRANSPLANTATION 
Biotechnology is the practical application of scientific 
knowledge acquired through research. The moral and ethical 
problems created by the development, test ing and use of 
advanced biotechnology cannot be ignored. In order to 
evaluate these processes, not only must we study their 
physical effects on both animal and human, but we must also 
evaluate the legal, moral and social context ln which they 
occur. These problems are of special concern 1n discussing 
xenotransplantation which involves the genetic modification 
and sacrifice of animais, and public risk. 
1. IMMEDIATE CONCERNS 
A. Animal Sacrifice for Human Life 
Xenotransplantation involves the breeding, genetic 
manipulation and sacrifice of animais for the prolongation of 
human life. Ethical 1ssues regarding the use of animal life 
for the benefit of humans have already been addressed ln 
Chapter 2 of this paper and need only be briefly considered 
here. If as humans, we have an obligation to protect nature, 
how do we balance that obligation wi th our obligation to 
humanity? Is the deployment of animals in this way a use or 
an abuse of nature? Are we prepared to use animais, in order 
to prolong our own lives? The individual hoping for an 
extension of life might have one reply whereas others might 
requ1re further debate. Is society prepared to accept the 
legally sanctioned existence of a procedure where it becomes 
necessary to pose the question. 
Until the first experiments are performed, it will be 
impossible to know whether pig organs will function properly 
in a human body, and experience teaches that early xenograft 
recipients will not have a good chance of survival. To the 
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patients themselves, awaiting certain and almost immediate 
death, the choice may not be difficult. Moreover, it will be 
made in the context of a doctor-patient relationship ~n which 
the best interests of each individual patient must be given 
priority, in which the physician hasan obligation to provide 
the best available treatment, and in which there must be sorne 
reasonable hope for success. 
Is it possible that palliative care would be the safer and 
more appropr~ate choice? In the Report of a 1983 workshop 
attended by members of the medical and scientific community 
including those working in the field of biotechnology, it was 
conc 1 uded tb'a t: 
"the dangers of suppressing essential innovation were 
considered less serious than the present uncontrolled 
proliferation of unproved technologies". 1 
Given the shortage of organs and assuming no alternative at 
this time, if i t is adjudged ethical to use and sacrifice 
animal life to save that of a human, such a procedure should 
probably not be used on human subjects un til i t has been 
tested on primates. The working party of the Nuffield Council 
on Bioethics accepts the use of very small numbers of primates 
as recipients of organs during the development of 
xenotransplantation as justified by the potential benefits if 
that procedure were to become a successful method of 
? treatment.~ However, ethicist A.L. Caplan poses the 
question: 
"Is it ethical to kill primates, even if only a small number, 
to demonstrate the feasibility of xenografting ~n human 
beings? If primate and humans have the same moral status then 
it is hard to see how the use of primates could be justified. 
1 . 1 t ?"
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Are humans and ape mora equ~va en s. 
He decides they are not on the grounds that humans, ~n 
general, possess capacities and abilities that confer greater 
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moral value upon them, such as family-feeling, protectiveness, 
shame, community-mindedness, a sense of history and a sense of 
responsibility . However, one need only open the daily 
newspaper to conclude that sorne of his criteria are of 
dubvious value. The criteria to be used in assessing relative 
value remain open for discussion. 
B. Genetic Mod ification of Living Matter 
The grounds for concern ln this area arlse from experlence. 
We have already seen what happened to Pig No. 6707. Similar 
experiments carried out in Great Britain and Scotland have 
produced ether plgs with physical problems. Billions of 
dollars are being spent on experiments to produce pigs, sheep, 
chickens and cattle for feed and growth efficiency. 
Researchers at the University of California have created the 
transgenic geep, a combination of sheep and goat. While most 
of this is done in the name of productivity and profit; sorne 
of it retains a side-show quality . We are sacrificing genetic 
integrity in an effort to produce bigger pigs, cows and sheep 
which can then be exploi ted on the commercia 1 market. The 
limits which have been set by regulation so far, apply to 
research performed at institutions, universities and 
hospitals, and funded by government and specifie agencies. 
Until there is a general law applicable to everyone , private 
commercial endeavour will remaln uncontrolled and public 
concern will remain well founded . 
When the AIDS m1ce were created there were those concerned 
about the danger of spreading disease . Many well known 
scientists argued that the planting of the human AIDS virus 
genome in mice would not likely result in the mice actually 
expressing the whole virus . Then Dr. Robert Gallo, one of the 
co-discoverers of the AIDS virus warned that use of transgenic 
mice for AIDS research could lead to HIV combining with the 
mouse's own viruses thereby resulting in a new potentially 
more virulent form of AIDS perhaps even capable of airborne 
transmission . Furthermore, any changes in the properties of 
4 
the HIV would render any research results open to question, 
and could render them ir relevant and even misleading. The 
warnings were finally heeded and the research stopped. 
But aside from the possibility of undesired and undesirable 
results, we must also educate the public so that, aware of all 
issues, it can decide, whether sorne genetic modification of 
animais in the hope of saving human lives, even if an assault 
on the dignity of the animal, is acceptable. If we respond in 
the affirmative, we must ensure control s so as to prevent 
commercial exploitation of those animais. 
C. Public Risk 
When the FDA approved transplantation of baboon marrow into an 
AIDS patient thereby improving the condition of that 
particular person, was i t, by permi tting the use of this 
technology risking another AIDS-like epidemie? This was the 
question asked by ethicist, Mark Hanson, a strong advocate of 
the study of moral questions and social 
new technology. He considers this 
practical public heal th problem and 
changes arising from 
a moral rather than 
concludes that where 
fundamental discontent is evoked by moral issues which arise, 
new perspectives should be sought to study the ever expanding 
control of medical technology over human life and ensure that 
we do not reduce the meaning of human existence exclusively to 
regulation and control. 4 
The real question here l.S how much are we justified l.n 
impeding scientific progress in order to protec t the public 
against unknown risk? 
Not only ethicists, but physicians as well, are troubled by 
this problem: 
"Clinicians and policy makers alike must recognize that 
although xenotransplantation promises benefits for specifie 
patients, that promise is accompanied by an unquantifiable but 
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undeniable potential for harm to the wider cornrnunity. Thus, 
in this new field, the determination of what constitutes an 
acceptable risk in the balance between caution and progress is 
a matter of public concern, not merely a private matter for 
. t d "d " 5 individual scientists, physicians, and pat1ents o ec1 e. 
Because the risk of disease transmission exista with 
xenotransplantation, do we, as individuals, have an obligation 
to society as a whole to refuse its possible benefits until 
such time as al!, or at !east most, risk has been removed? To 
what extent. should the individual be obliged to consider 
public good and public risk? Do we want him to have that 
choice? 
The British Advisory Group on xenotransplantation in 
considering whether it would ever be ethically acceptable to 
proceed with xenotransplantation, concluded that it would: 
" ••• at the stage when it is considered that a full 
investigation of potential infection risks has been carried 
out, and the risks have been shown to be within tolerable 
margina, it would be ethically acceptable to proceed. This is 
subject to there being a system in place to monitor the 
emergence of any unusual disease or any unknown pathogens and 
to require, as a consequence, that appropria te addi tional 
research be completed in a proper fashion." 6 
Health Canada is not so sure and in its 1997 Information sheet 
states: 
"No medical procedure is without 
xenotransplantation could be considered 
safety standards would have to be met. 
risk. Be fore 
in Canada, strict 
Whether Canadians 
would fee! comfortable accepting a degree of risk in return 
for the potential benefits of such transplants is still open 
to question". 7 
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o. Informed Public Consent 
Because of the potential that the public may be affected by 
xenotransplantation, we must decide how rouch information 
should be given third parties who come in contact with the 
recipient such as health care workers, relatives and friends. 
And again, should their consent be required? 
A risk to 
determining 
that risk. 
the public requires a public mechanism for 
the acceptability of, and method of consent to, 
Furthermore, the standard model of individual 
informed consent to medical interventions must be modified, 
since the risks involve third parties thereby requiring the 
monitoring of not only the recipient but his close contacts as 
well. 8 The patient and others will have to commit to 
participate in such monitoring for an unknown, and perhaps 
extensive, period of time. Patients would have to agree not 
only to the risks attendant to a transplant procedure, but 
also to possible quarantine, to modifications of the 
guarantees of confidentiality and to the surrender of their 
right to drop out of the study. In order to protect the 
public at large, the trans-species transplant could not be 
allowed unless the patient and those close to him agreed to 
these onerous con~itions. 9 There would have to be a trade 
off of individual freedoms for potential persona! benefit as 
well as for public protection. 
To be informed, the public must be educated. This can be done 
through extensive public discusssion defining the ethical 
concerna, the potential risks and the ultimate benefits of 
xenotransplantation to society as a who le. This has been done 
before. In 1984 when the Medical Research Council of Canada (MRC) established a Standing Committee on Ethics in 
Experimentation, approximately 750 written submissions were 
received from various individuals and groups including 500 
from outside the research community. Meetings of the 
committee were open to the media to encourage public interest 
and input, and the discussion document produced was 
7 
distributed to approximately 2000 persons. 
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In England, the Working Party of the Nuffield Council agreed 
early on that it was important to collect the views of all 
those interested in xenotransplantation. It contacted 130 
organizations and individuals representing a variety of 
interest groups as well as members of the pub! ic • It 
considered that this consultation formed an important 
h . 11 component of its consideration of t e ~ssues. 
The u.s. Public Health Service, prior to publishing its 
guidel ine on Infectious disease issues in xenotransplantation, 
called for · public submissions and offered copies of the 
h d . 12 Th U S document upon request to anyone w o wante ~t. e •• 
Food and Drug Administration Representative commenting on the 
Guideline suggests a Proposed Rule on Public Disclosure of 
Gene Therapy and Xenotransplantation Clinical Trials as well 
as a Proposed Rule on Xenotransplantation "to provide notice 
and invite public comment on the regulation of all 
xenotransplants as biologies". 13 This document also states: 
" P"u b 1 i c a w a rene s s and und e r s ta nd i n g of 
xenotransplantation is vital, because the potential 
infectious disease risks posed by cross-species 
transplants extend beyond the individual patient to the 
public at large. The Proposed Rule on Public Disclosure 
of Gene Therapy and Xenotransplantation Clinical Trials 
delineates the agency's position that disclosure of a 
select subset of information from all INDS relating to 
xenotransplantation and human gene therapy is essential 
to allow for public discussion and consideration of the 
associated public health and ethical issues." 14 
Health Canada in its bulletin on xenotransplantation issued in 
November 1997 announced the establishment of an Expert working 
Group as weil as the publication of proceedings of the 
national forum about to take place. Copies of these 
proceedings were to be made available to anyone who wanted 
them and commenta received were to be considered in 
8 
15 formulating a risk management strategy. 
Xenotransplantation is a potential treatment procedure which 
may put the public at risk. Consequently, public awareness 
and public input are necessary and are to be achieved as 
rapidly as possible so as to avoid unnecessary withholding of 
therapy from those in need. We can only balance the uncertain 
risks to society as against the certainty of organ failure for 
the individual with the consent of all involved parties. Such 
consent requires knowledge and understanding. 
2. LONG TERM CONCERNS 
A. The Mutual Impact of Technology and Culture 
The long term effect of these efforts at preserving human 
life, should they succeed, are being assessed and questioned. 
What are the social and economie ramifications to a population 
that can survive to be over one hundred years old? Is this 
achievement really a benefit to mankind? How will this 
technology change our social structure? Ethicist A.M.J. Henk 
states: 
"Technology is not only a cultural product, but itself a 
producer of cul ture ••••• It is better to say that a 
technology constitutes a particular practice which is 
medical and social at the same time." 16 
The fastest growing segment of the population consista of 
those over eighty years old; twenty five years in life 
expectancy has been gained during the twentieth century, more 
than twice the gain in all previous human history. Children 
born in the modern world have a projected life span that is 
ten to twelve years longer than that of their counterparts 
born ten years earlier. 17 Religious and educational 
institutions must adapt to an older population, housing must 
be al tered to accomodate its members, fashion and 
entertainment must cater to them, insurance and financial 
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institutions must devise pol icies useful for them, heal th 
institutions must provide facilities, equipment and programs 
to care for them. 
The International Council for Global Health Progress sponsored 
by the United Nations Educational, Scientific and Cultural 
Organization recently met 1n Paris and called for a new 
constructive vision of an aging society. It felt that the 
medical profession had a responsibility to help society adapt 
to this radical social change which it has created . 
Biotechnology, a product of our culture, is also changing that 
culture, our lives, how long we live and how we live. Such 
radical changes of social structure create insecurity which 
generates fear. That fear is aroused as our natural world 1s 
changed by scientific advances and by a technology which 1s 
able to modify and create life. 
As science develops the tools which may be able to control 
natural selection and evolution and redesign the animal world, 
biotechnology is seen by sorne as a monster which can remove 
our huma ni ty. But i t can al so cure disease and accord us 
additional life. It is the question of how it is to be used 
and by whom which must be addressed. 
B. Man and Technology: Which 1s 1n Control? 
If we accept that the mean1ng of human existence should not be 
reduced to control by biotechnology, where do we draw the line 
between such control and the ability to maintain and prolong 
life. How do we reconcile technology which benefits mankind 
with that which controls it? Our search for a scientific 
explanation of 1 ife has given ri se to the technology of 
transgenic breeding and cross-species transplantation which ln 
turn serves as a tool to preserve that life. 
Germline gene alteration for therapeutic purposes means that 
the changes are passed on to future generations. It is an 
intentional interference with natural propagation while 
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ignorant of the possible total effect on the body as a whole. 
To date, we have lived with the cultural assumption that 
control over natural processes lS both appropriate and 
desirable. This lS fortified by an interpretation of the 
bible which grants humans dominion over nature, and instructs 
them to master, improve, preserve and heal it. This is also 
compatible with the goals of medicine and scientific research 
to heal and restore. Today we are able to do this in part 
through genetic intervention. The end purpose of genetic 
research is to fight disease and no one can argue with the 
validity, acceptability and worthiness of that goal. It is as 
we apply the knowledge so obtained that we must guard against 
misuse of the resultant technology. 
Knowledge is never ln itself morally unacceptable. But who is 
to control its application? Who 1s to control the 
manipulation of life? Is it to be the scientist endeavouring 
to uncover pure know ledge and tru th, commercial interests 
motivated by profit, or political interests lusting after 
power? The question posed by Rebecca Eisenberg, writing on 
patent rights and the human genome project, lS, if germline 
genetics becomes a technique to improve the human race, who 
will decide what constitutes an improvement? In her opinion 
such a decision would be tantamount to playing God and such 
acting must be controlled. Only by such control can we ensure 
18 
that man controls technology and not the reverse. 
C. Public Morality 
The Quebec Conseil du statut de la femme, ln emphasizing the 
need for vigilance with regard to new reproductive 
technologies, espoused the idea of scientist Joel de Rosnay 
that man has become the engineer of man and that we must think 
about what we are doing. 19 Sh deliberation takes place 
within a framework of social values. 
Every society or culture, 
imbued with a built-in 
at any specifie period of time is 
set of norms handed down from 
11 
generation to generation . Because our own North American 
society is composed of many different groups, moral consensus 
is often difficult, if not impossible, to attain. This was 
reflected by the recent Tri-Council policy statement on 
Ethical Conduct for Research Inval ving Humans ln which a 
section lS to be devoted to research inval ving aboriginal 
peoples. In so doing, the Tri-Council has acknowledged that 
"aboriginal peoples have distinctive perspectives and 
understandings embodied in their cultures and histories" . 
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We see constant examples of differences with regard to such 
issues as common law marriages, socially accepted ac c ording to 
recent statistics, but not yet protected by the civil code of 
Quebec, same sex marriages, still not accepted either socially 
or legally, euthenasia, assisted suicide, mention of the 
supremacy of Gad ln the Canadian Charter of Rights and 
Freedoms, use of foetal tissue ln germ cell research, 
abortion, the teaching of religion as part of the school 
curriculum. All the se lSSUeS are as y et unressolved ln our 
non homogenous society. 
The Law Reform Commission of Canada 
21 held that principles 
could not be found by reliance on market research or religious 
doctrine, but could only be discovered by reference to 
fundamental social values, without which all social life would 
be impossible, and especially the sanctity of human life and 
inviolability of the persan. An act, to be acceptable, must 
not seriously harm ether people, or so seriously contravene 
our fundamental values so as to be harmful to society. 
What are the fundamental values of our society? and does the 
process of xenotransplantation so contravene them as to be 
considered harmful to that society? 
It is the basic values of our society that have glven rlse to 
those laws, regulations, guidelines and concepts discussed ln 
Chapter 3. Those values are expressed in the Canadian Charter 
of Rights and Freedoms 22 which recognizes the supremacy of 
Gad and the rule of law, and the Quebec Charter of Rights and 
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Freedoms 23 which advocates respect for the dignity, privacy, 
rights and freedoms of the individual in conjunction with the 
rights of others and the common well being. Among the basic 
rights g~ven members of our society are autonomy and freedom 
of choice. These provide a moral boundry for scientific 
research by making experimentation us~ng human subjects 
dependent upon consent. However, such consent would never 
validate scientific enquiry which was judged to be morally 
wrong and in contravention of our value of life. The problem 
arises in assessing the value we give to life, the extent of 
our responsibility for it, and the strength of our power over 
it. If we are to uphold our fundamental value system, 
exerc~se of that power must never be arbitrary but rather an 
expression of reponsibility. "Une société que s'habitue à 
s'octroyer ainsi un pouvoir de vie et de mort sur cela même ? , 
qui est confié à sa responsabilité, est une société malade." _q 
There are those who would say the same with regard to our 
power over animais and nature. 
Power must be 1 imi ted as is our guarantee of rights and 
freedoms which are " subject only to such reasonable limits 
prescribed by law as can be demonstrably justified in a free 
and democratie society." 25 The Uni versai Declaration of 
Human Rights provides that the exercise of rights and freedoms 
is subject to such limitations "as determined by law solely 
for the purpose of securing the recognition and respect for 
the rights and freedoms of others and of meeting the just 
requirements of morality, public arder and the general welfare 
26 
in a democratie society." 
Failure to treat life in a responsible way results ~n or is 
tantamount to exploitation. Sorne of the ethical problems to 
which this gives rise are clearly set out by ethicist Mary ?":' 
Mahowald, and scientists Jerry Silver and Robert Ratcheson ~~ 
as they attempt to balance the benefit of the therapeutic use 
of fetal tissue with their concern for the possible 
exploitation and commercialization of fetuses. They are also 
concerned that by using the body of one woman for the sake of 
13 
another there is a risk of demeaning human life. They declare 
that scientific progress and therapeutic effectiveness do not justify using people. They fear that from transplanting 
tissue of dead fetuses may come use of living albeit non 
viable fetuses, from transplanting brain tissue to whole 
brains may come harvesting whole organs from people definitely 
dying but not yet dead. When does the life-saving motive turn 
into one of profit making? When are women paid to become 
pregnant ~nd then abort so that the fetal tissue can be used? 
Preventive . wedges must be put 1n place and a degree of 
aversion can serve as such a wedge. Is the breeding of 
fetuses ~or tissue so different from breeding pigs for 
xenotransplantation? 
It is obvious that we are still struggling with these 
questions, and will probably continue to do so. But the 
struggle becomes an end in itself for it keeps the process of 
evaluation ongoing. 
"Ethical deliberation does not take place in a vacuum, 
however, but 1n a social and historical context that 1s 
continually changing. There are no timeless solutions, and 
ethical debate cannot be separated from the domain of social 
life. Equally, people's moral convictions are not just rooted 
in the force of tradition but are the results of sincere and 
mature reflections. 
"Wherever people are involved 1n making judements about 
questions of life and death - whether as scientists, doctors, 
patients, relatives or loved ones - these judgements are made 
against the background of their relationships wi th human 
beings and with other animals. These relationships are 
already in place as the ground from which any moral or ethical 
system grows ...• Thus, a sense of what may reasonably be done 
to human beings and to other animals necessarily depends on 
the sensitivity developed through these relationships." 28 
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o. Commercialisation 
Wh en do es the life-saving motive tu rn into one of profit 
In the opinion of one author, science as pure making? 
research is modern myth. It 1S "propelled as much by a 29 
" and the waging of war as by curiosity ... . commerce 
t it Fetal tissue may be useful and necessary but to accep as 
a commodity to be traded is considered by our society as 
damaging to human dignity, denigrating of respect for the 
foet.us and · encouraging of the exploitation of women · The 
Committee on new reproductive technologies of the Quebec Bar Associatio~ 30 gave as a guiding principal of law reform in 
this area, human dignity, and formai prohibition against any 
kind of commercialisation. Otherwise we risk the 
dehumanization, 
procreation. 
vulgarization and commercialisation of 
CommercializatioP brings to mind principles of marketing and 
the idea of marketing better organs or improved genes 1s 
repugnant. But surely the goal of curing, treating, and 
saving 1 ives, should supercede our concern for the use or 
exploitation of animais for organs. Perhaps it's a question 
of degree and it is the circumstances 1n which these acts are 
performed which must be ev al uated and control led. The re 
should be nothing worse about purchasing tissue or organs in 
order to survive or lead a better life, than there is with 
purchasing a pace-maker or prosthesis. However, the 
manufacture of the latter is controlled and so should be the 
production of the former. It 1s abuse which must be 
prohibited, not the acts themselves. 
There are choices to be made at all levels. Individuals must 
decide whether or not to accept animal organs, hea 1 th 
professionals whether or not to transplant them, the public 
whether it is prepared to accept the risk and the government 
how it is to regulate the procedure in all its animal and 
human aspects, and how the procedure, once accepted, is to be 
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financed. And each of these groups must decide whether the 
moral obligation exists in saving the animal and sacrificing 
the human or in sacrificing the animal to save the human. 
A distinction must be made between fundamental research and 
applied science, that is, biotechnology. Knowledge can be 
valuable or lethal; it can be used for the benefit of mankind, 
or it can be comrnercially exploited. It does not always walk 
hand in hand with responsibility and outside regulation must 
provide guidance and control. When Einstein discovered his 
famous formula, it is doubtful that he pictured its result 
falling on Hiroshima. It is by law and regulation that we can 
control the potential for Frankenstenian use of genetic 
manipulation and cross species procedures. Although such laws 
exist with regarù to experimentation, another field of law, 
patent law, has shown itself to be less aware of, or perhaps 
less concerned with, the dangers of exploitation. 
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CHAPTER 5 - THE PATENTING OF LIVING MATTER 
1. INTRODUCTION 
Any discussion of the commercialization of living matter would 
be incomplete without a review of how Patenting has been 
applied to such matter and to genetics . 
According to the United States Patent Act 1 and the Canadian 
Patent Act 2 " ••• ,any new and usefu 1 process, machine, 
manufacture or composition of matter ... " may be granted patent 
protection. In addition, on April 21, 1987 the U.S. patent 
office issued the following statement : 
"The Patent and Trade-Mark Office now considers non-naturally 
occurring non-human multicellular living organisms, including 
animals, to be patentable subject matter within the scope of 
35 use 101". 
Patent law 1s based on the economie desirability of sharing; 
share your invention and the government will protect it. Thus 
sec recy is avoided and economie growth promoted. It 1s 
generally accepted that in order maximize the potential for 
economie growth, the patent system must be receptive to new 
and useful technologies. 
Biotechnology has now enabled man to create and modify life 
forms, something unforeseen when patent law first came into 
existence. The question threfore arises, if man is able to 
create a form of life, does he have the right to patent that 
creation. The law has replied, albeit not uniformly and not 
consistently. 
2. HISTORICAL PERSPECTIVE 
A. The 1970s 
In 1970 the Exchequer Court of Canada, refused to patent a new 
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method for surgical bonding of body tissues on the grounds 
that the situation was one of "use" and not "invention", and 
that material prepared for medical use was not patentable. It 
was held that to grant a monopoly would hamper the medical 
profession, and it was therefore not in the public interest to 
do so. 3 Then in 1971, a microbiologist named Chakrabarty, an 
employee of General Electric, fused the genetic material from 
three types of bacteria with a fourth thereby producing a new 
strain of bacterium engineered to degrade crude oil. He 
applied to patent his creation with an appetite for o il. The 
u.s. patent office declared the organism was "alive" and that 
had President Jefferson intended 1 ife to be patentable 1n 
1793, he would have so declared. 4 
Chakrabarty and General Electric appealed to the Court of 
Patent Appeals which reversed the decision of the examiner a nd 
declared that the fact that the organism was alive was without 
legal significance. In an attempt to di lute possible 
repercussions from such a decision, the court also remarked 
that the organism was more akin to a chemical than to a plant 
. 1 5 or anJ.ma . 
B. The 1980s 
Upon appeal, the Supreme Court was at first reluctant to 
patent life stating it was up to Congress to amend the patent 
law if it so wished. However it eventually reversed itself 
and on March 17, 1980 in a five to four decision held that 
Chakrabarty' s invention was patentable. 6 It supported and justified this decision by declaring that the relevant 
distinction was not between living and inanimate things, but 
whether a living product c ould be considered as a man made 
invention. To Chief Justice Warren Burger the oil-eating 
microbe was Chakrabarty' s invention and not a product of 
nature and therefore patentable. The intention of the Patent 
Act was to include anything made by man as opposed to anything 
existing in nature. The dissenting justices held it was up to 
Congress and not the Courts to extend the field of application 
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of the Patent Act. Amazingly, the court did not appear to recognize the implications of its decision and, suffering from a severe case of tunnel vision, stated that this was a narrow case which did not affect the future of scientific research. 
Meanwhile, in Canada, 1n 1981 a Patent was sought for an 7 invention which divided sperm into mal e and female elements . The examiner rejected the request because living matter was inval ved. This decision was reversed by the Patent Appeal Board which held that sperm cannat reproduce themselves and therefore are not 1 iving organisms, only part of a 1 i vi ng organism. Moreover, synthetically separating sperm was seen as an artificial process which would not occur in nature, and consequently this was an invention and patentable. However , as there was sorne concern that the procedure could affect methods for controll ing human population, the appl ica nt agreed to limit the request to non-humans. It should be noted that the claimant was not trying to patent sperm, but a process for separating its elements. 
In the Abitibi case 8 which directly followed the Chakrabarty decision, an application was made for a microbiologica l culture which digests spent sulphite liquo r from pulp plants. The Patent Appeal Board citing the Chakrabarty dec ision held this invention was a non-naturally occuring manufacture of a micro organism and therefore patentable. 
This was, in turn, followed in the Connaught Laboratory case 9 in which a patent was claimed for a new bovine cell line. The Patent Appeal Board concluded that: 
" .. we can no longer be satisfied that at law a patent for m1cro-organism or ether new 1 ife forms would not be held allowable by our own courts." 
The late 1980s produced two major leading cases, one in the 
The Canadian case is the Pioneer Hi-
was an application for a patent for a soybean 
U.S.A and one in Canada. 
Bred case. This 
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developed from cross breeding. The lower tribunals rejec ted 
it because the subject, namely, a process for producing a new 
genetic strain or variety of plant or animal, was no t 
patentable. The Supreme Court rejected i t for rea sons of 
procedure. 
In refusing to grant the 
stated that he had a duty 
outcome 10, and declared: 11 
patent, the Patent Commissioner 
to consider public interest in the 
" ... there are limitations in Canada to the types of ende avours 
worked by . humankind that may receive patent protection." 
The decision was appealed to the Federal Court of Appeal where 
Marceau J. stated: 
"The assumption that life forms are not patentable subject 
matter has been up to recent years so generally accepted that 
nobody would even have thought of disputing its validity in 
court." 12 
He did, however, acknowledge that with the 
advances 1n biotechnology, they might not 
excluded. Refering to the USA cases he states: 
spectacular 
forever be 
"I am prepared to accept that Canadian Patent legislation does 
not support the assumption that life forms are definitely not 
patentable". 13 
He then decided the soybean was not an invention under section 
2 of the Act and was thus able to refuse the patent under the 
invention definition and avoid any interpretation of his 
decision as being an absolute prohition of the patenting of 
all life forms. 
14 The case was taken to the Supreme Court of Canada where, 
in spite of the fact that it was recognized and acknowledged 
that the patentability of life was at issue, refusai to grant 
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the application was based on the grounds that proper 
application procedure had not been followed. 
Chief Justice Lamer distinguished between hybridization, which 
he describes as a natural reproductive process guided by human 
hand, and recombinant DNA technology which consists of the 
alteration of genetic codes by intervening within the gene 
itself. He categorized hybridization as a natural 
reproductive process guided by human hands and distinguished 
it from the alteration of genetic codes ultimately resulting 
1n the creation of a new gene. He expressed this distinction 
as follows: 
"The courts have regarded creation following the laws of 
nature as being mere discoveries the existence of which man 
has simply uncovered without thereby being able to claim he 
has invented them." 15 
Since the Abitibi case in 1982, patents have been granted in 
Canada for new microorganisms such as bacteria, yeast and 
mold. However, in spi te of the statement in the Connaught 
Laboratories case that it could not be affirmed that other 
1 ife forms would not be cons ide red patentable, the patent 
office and the courts refused, 1n the 1989 Pioneer Hi-Bred 
case to grant a patent for soybean breeding. Moreover, the 
Patent Office Manual issued 1n 1990 16 has declared an 
absolute prohibition on the patenting of higher life forms. 
However, this begs the question as to what constitutes a 
higher life form. 
While the Canadian application to patent a soybean was being 
refused because i t is a 1 ife form, an Amer ican patent was 
granted for a mouse. New technology enables scientists to 
create human disease models from genetically engineered 
animais. The animal thereby becomes susceptible to a 
particular human disease which can then be studied using the 
animal rather than a non-human primate. 
6 
In 1988 the US patent office granted the first patent on a 
living animal to the Dupont company, for the Harvard 
OncoMouse; a transgenic meuse bearing an activated meuse 
oncogene in its genome making it more susceptible t o cancer. 
The claim was also granted "for its ancestors at an e mbryonic 
stage." 17 
Public outcry 1n the United States resulted 1n the tabling of 
a Moratorium Bill on animal patents in 1990 based on profound 
economie, environmental and ethical issues not yet addressed 
by Congress. The bill never passed, and since 1992 patent s 
have been issued for a genetically engineered virus r e sistant 
meuse, a deficient 1mmune system meuse and an enlarged 
prostate mouse. 18 It would seem that in the United States, 
Chakrabarty was the first step on the slippery slope. 
The European Patent Office (EPO) first rejected the claim to 
patent the OncoMouse
19 and stated there wer e mo ral and 
ethical issues it did not feel qualified to decide. The 
technical Board of Appeal ruled the introduction of a gene was 
a technical process and not a biological one,
20 and sent the 
application back to the examiner's office which then decided 
the OncoMouse was not an "animal variety'' within the meaning 
of the act. It weighed the detrimental effects and risks to 
the -animal, the moral issues and the interests of mankind in 
curing and preventing disease, and decided that, on balance, 
patenting the oncomouse could not be considered immoral or 
contrary to justice. It maintained, however, that its 
conclusions applied only to that particular case and might not 
be the same with another case. 
In reaching its decision, the European office had t o consider 
the European Patent Convention exclusions applying to: 
sec 53 (a): "inventions the publication or exploitation of 
which would be contrary to ordre public or morality, provided 
that the exploitation shall not be deemed to be so contrary 
merely because it is prohibited by law or regulation in sorne 
or all of the contracting states." 
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sec. 53 (b) "plant or animal varieties or essentially 
biological processes for the production of plants or animals; 
this provision does not apply to microbiological processes or 
the products thereof." 
The European office had a difficult time reconciling the law 
with new technology and a European Commission was created to 
study the issue of patenting biological material. This body 
has issued a proposed directive which specifically excludes 
from patent protection the human body or parts, as well as 
processes for modifying the genetic identity of animals which 
might cause them suffering without any benefit to man. 
As the granting of patents for 
com~onplace in the 1980s so did s1gns 
1984 the Hagahai People came out of the 
biotechnology bec ame 
of exploitation. In 
forests of Papua, New 
Guinea, to obtain medical help. American anthropologist Carol 
Jenkins came to give that help and, in so doing, developed a 
trusting relationship with this unsophisticated people. In 
order to diagnose their problem and ascertain their needs she 
took blood samples and it was discovered that their blood 
contained unique genetic characteristics that potentially 
offered resistance to certain types of leukemia. More blood 
was taken. The Hagahai were given soap and matches in return, 
but were not told that sorne of their blood was being used for 
research. In particular, the cell line of a specifie 28 year 
old male contained a retro-virus that held the possibility of 
developing screening kits and vaccines. The NIH obtained a 
patent for his germ line. Journalists eventually advised the 
Hagahai that money was being made with their blood. Although 
they were angry, the NIH having withdrawn the patent under 
international pressure, they did not pursue the matter 
further. 21 
John Moore felt differently. His cancerous spleen had been 
removed 1n 1976 and his cell line was found to have 
interesting and unique characteristics. Unknown to him, his 
doctor patented his cell line and the patent was purchased by 
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M M e utilized the a Swiss pharmaceutical company· r · oor 
services of the American courts in giving vent to his fury. 
Although his proprietary rights to his own body products were 22 
. t f recognized by the Court of Appeal the Supreme Cour o 
california2J held he had no rights in the patent. On the 
other hand the court also held that the physician had an 
obligation to reveal his economie interest in the use of the 
cells as such interest might affect his judgement with regard 
treatment. And so Moore' s a ward was based on fai 1 ure to 
advise an~ lack of consent r2-ther than on loss of profit. 
Moore's autonomy and right to consent were recognized, his 
right not . to be exploited was not. 
c. The 1990s 
Patents for higher life forms have now been issued in France, 
the U.S.A., Japan and Europe. We've come a long way from the 
decision that public interest necessitated refusal of patent 
protection for surgical treatment. Canada rema1ns cautious, 
and on August 4th, 1995 the Canadian Patent Office held that 
claims to a transgenic non-human mammal (Harvard's OncoMouse) 
were not patentable under section 2 of the Patent Act. This 
decision was maintained by our Federal Court which held that: 
1. Harvard had received a patent for the process of inserting 
a gene into a mouse egg and not for inventing the mouse. 
Other than the transgene, all characteristics of the mouse 
exist independantly of human intervention. 
2. What Harvard had invented, and for which it was entitled 
to patent protection, was the plasmid and the process of 
injecting it into the fertilized mouse egg. However, a patent 
over every descendant mouse possessing the transgene was 
refused. Harvard invented a process for inserting a new gene; 
the laws of nature produced the mouse. 
3. The mouse is reproduced by ordinary breeding and under 
Canadian patent law the invention must be reproducible to be 
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patentable. The reproduction, ln this c ase, 1s according to 
the laws of nature. 
4. Complex life forms do not fit into the prov1s1ons of the 
current Patent Act , and it is up to Parliament to make the 
h . f "t . h 24 necessary c anges 1 1 so w1s es . 
The Supreme Court has yet to rule. 
Our Patent Laws were not meant to caver biotechnological 
situations as they exist today . Until they are changed or 
modified to deal with the advances 1n biotec hnology, the 
courts and judges do what they can to satisfy public op1n1on 
and conform with community morality while acting to protect 
commercial interests. 
Defining 
illicit 
patents 
such terms as ordre mora 1, public interest , and 
abject, 1s problematic, and the grounds on which 
are granted or refused seem to differ at the 
administrative and judicial levels. The patent exam1ner 
refused to grant a patent for 
it consisted of a life form. 
by the highest court on the 
Chakrabarty's invention because 
This was eventually overturned 
grounds that , although a life 
form, it was man made. The patent commissioner in the Pioneer 
Hi-Bred case refused the patent on the grounds that life forms 
are not patentable; the refusal of the Supreme Court was on 
the basis that the application procedure had not been properly 
followed. It is obvious that there are great differences of 
opinion among those who must decide both with regard to the 
decision to be made and the reasons for making it. 
3. THE ETHICAL PERSPECTIVE 
In considering patent applications, the examiners and judges 
must interpret the law as it exists within a framework of 
competitive econom1cs, their personal values and public 
op1n1on. 
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Patent law exists ln an indus t ri a l context and appl ies t o 
abjects, chemicals, designs and processes . Yo u c o uld patent 
a mou se trap but not a mou se . Once t h e g e net i c ma k e up o f 
living things could be alter e d, resea r c h e r s c l a ime d a n 
inv e ntive step in the o rganism it se ]f, and wa nted to prot e ct 
their expensive and valuable i n vestme nt . Th is r a1se s suc h 
questions as: should we b e c on s ide r i ng 1 i v i ng th i ngs et s 
artic le s of manufacture? Is a copied h uma n gen e a dis c overy 
or an invention? Is patenting sec tion s o f t he human genome an 
abuse of human dignity or part of commerc i al e nterprise? 
Transgenic animals are valuable ln me di ca l and scientif ic 
research. One meuse secretes a protein which dissolves bJood 
clots; the onco -mouse is more sus c eptible to c anc e r th e reby 
lessening the amounts of carcinogens require d for testing; a 
goat wi th a human gene has now been br e d so that when i t 
reaches maturity its milk can be used to produce a treatment 
drug the nature of which is as yet unrevealed. 25 Transgenic 
pigs are being created to serve as organ donors for human 
patients. But by encouraging such inve ntions, namely, the 
creation and modification of life, are we devaluing life; are 
we offending public morality? 
A. Animal Patenting 
Animal patenting glves ownership of an i mals; the Onco-Mouse is 
owned by Dupont. The animal becomes a set of molecules 
available for human manipulation. Does this necessarily mean 
we are playing Gad? After all, we have been involved ln 
selective animal breeding and animal eugenics for years. 
The Judge ln the Abitibi case stated at page 90: 
"If an inventer created a new and unobvj_ous insect which did 
not exist before (and thus is not a product of nature), and 
can recreate it uniformly and at will, and it is useful (for 
example to destroy the spruce budworm) then it lS every bit as 
rouch a new tool of man as a micro-organism. With still higher 
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life forms it is of course less likely that th e inv ent e r will 
be able to reproduce it at will and c onsi s tently, as mo re 
complex 1 ife forms tend to vary mor e from individua 1 to 
individual. But if i t eventually becomes p o s s ibl e to a c hieve 
such a result, and th e ether requirements o f pate nt a bility are 
met, we do not see why it should b e t r e at e d diff e r e ntly." 
The courts appear t o say that if you c an c reate life, you c an 
own it. They are not bothered by th e ultimate creation of 
human life apparently on the grounds that it is not likely to 
occur. Should it o c cur, however, it will h a v e to be treated 
differently, as the owne rship of anoth e r huma n is slavery, 
currently prohibited by law. 
B. Human Patenting 
The US patent office stated 1n 1987 that human life 1s not 
patentable; a property right in a human being is prohibited by 
the United States Constitution, and s 1 avery 1s no longer 
permitted. 
Who would own a genetically engineered human? Wh at 
proprietary rights could the owner exercise? Can we repeat a 
form of slavery with a human-chimpanzee genetic mixture? Who 
would own the Chuman? 26 Would such a being have the same 
rights as a Downs Syndrom child? 
treated 
forms? 
as patentable subject 
Do they fall within the 
If m1cro organ1sms are now 
matter, why not higher life 
defini ti on of "invention"? Is the re an ethical argument 
Should humanity limit against granting such patent rights? 
its attempts to understand the universe? or only to own it? 
C. The Argument 1n Faveur of Patenting Life 
If the patent system 1s intended as a tool for economie 
growth, should it even be considered ln conjunction with 
ethical concerns regarding biotechnology? 
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Salomon Avisar speaks on behalf o f t hose l n fa ve ur of 
patenting 1 ife . 
benefits. 
He sees the 1ssue l n te r ms o f r i sks and 
To Mr . Avisar " ... the test for d etermi n i ng wh e th er t o proceed 
with technological progress has neve r h een a nd ca nna t be th e 
mere p o tential for ri s k. The a p p ropr iate s tandard f o r 
measuring the merits of c hange lS t he prove n e xi s t enc e o f 
unacceptable risk." 27 
Risk is only unacceptable where it c an not b e null i fi e d o r 
controlled, or where it is not just i f i abl e hav i ng r e ga rd t o 
the be nef i ts of the pa rticula r tech no 1 og i ca 1 a d va ne e. We must 
deal with potential risk ln a fa i r a nd r a tional manner; this 
is what constitutes risk management. 
Absolute prohibition is "an arbitra ry and r e fle xi ve reaction 
to the potential for risk c ommon to all tec hno logic al progress 
- a bid to alleviate risk by attempting t o pre serve the status 
28 quo." Cars brought the ri sk o f ace ide nt s; c omputers 
changed the way we live and brought th e risk o f unemployment . 
No one would suggest that we return to 1 ife wi thout the se 
inventions . 
Avisar argues 
justifiable as 
that patent prohibition lS not rationally 
a means of alleviating risk and may remove 
incentive for res~arch and investment. Moreover, the inventer 
can market his product anyway or seek ethe r protection . Less 
disclosure inhibits accountability and Jess acountability may 
result in greater potential for risk . Res e arc h is world wide; 
changing the patent laws cannat stop it. 
"A prohibition on patenting fails as an implement of social 
policy in that it seeks to deny to humanity an opportunity of 
capitalizing on the potential benefits of technological 
?9 
change ." -
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"Humanity can and should strive to 
for its common benefit, provided 
vigilant about how that knowledge 
shape knowledge and science 
that it is prepared to be 
. d " JO 1s use • 
Denying patent protection does not control the potential risks 
and benefits of biotechnology. The patent does not accord the inventer the right to manufacture and produce; it m~rely prevents ethers from doing so. Refusai of a patent does not 
mean the inventer must stop producing the item, it rather permits anyone else to produce it as well. Holding a patent 
on a gene does not confer ownership; it only provides 
temporary legal protection against comm~rcialization of the 
invention by a third party. 
Nobody owns life, nor should they be permitted to do so, but 
we cannet insulate ourselves from international practice and 
commerce. We must crea te a regula tory environment which fosters Canadian biotechnology research without violating Canadian moral standards. 
D. The Argument Against the Patenting of Life 
On July 16, 1997 the European Parliament approved a European Commission directive that would grant corporations the right 
to patent "genes, human cells, body parts and organs and whole plant and animal varieties and parts thereof." 31 Excluded 
were whole humans and human embryos. There was sorne ambigu ity 
with regard to cloned humans and human parts. The 
unidentified author of a comment appearing in the Earth I s land Journal is of the opinion that allowing patents on life for the sole benefit of the large biotech companies shows a deplorable lack of democratie responsibil i ty. The rul ing 
makes human 
nothing more 
beings and the 
than resources 
agricultural corporations may 
is reduced to the status of a 
entire biotic community into 
over which pharmaceutical and 
vie for ultimate control. Life 
marketable commodity. 32 
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Dr. Donald Bruce, speaking for the European Ecumenical 
Commission for Church & Society, presents the argument against 
the patenting of life. Stating that anything biological can be 
patented negates the basic distinction between discovery and 
invention, making the distinction between animate and 
inanimate material irrelevant. There 1s no longer any 
difference between living organisms and non living . things, 
between discoveries in nature and products of human invention. 
The demands of commerce take precedence over respect for 
creation, and commercial potential becomes the decisive 
ethical criterion. Animate matter should obtain its identity 
and relevance by its relationship to what is living and not 
from what links it to its chemical composition or to 
functional industrial ut il i ty. Nature should not be seen 
. . 1 . 1 33 pr1mar1 y as a commerc1a ressource. 
Dr. Bruce argues that econom1c growth should not be the 
primary social criterion for biotechnological innovation to 
the exclus ion of hGman, social, environmental, moral and 
religious, components. Inventions should not be viewed 
primarily with regard to their value as economie entities, but 
with regard to their intrinsic value and their desirable 
impact on society. Now that the scope of patenting has 
increased from inanimate to 1 iving organisms, the ethical 
dimension becomes just as central and integral to the patent 
process as the criteria of novelty, inventiveness and 
industrial application. Perhaps what we need is a separate 
intellectual property patenting system. 34 
Because a human technique exists to synthesize the same entity 
as a natural product or organism does not mean that the 
natural form of the product should be considered a human 
invention. When inventors manipulate a design already found 
in nature they do not introduce a new design of their own. 
Intellectual property does not include objects, such as 
natural forces and materials, which the individual does not 
design. The organism may be al te red from its na tura lly 
occurring state by the application of a novel process to 
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natural mate rials, but the element of design resides in 
nature. The process can be patented but not the product itself. A distinction must be made between manipulating or 
changing a genome and designing or inventing one. There is no 
ethical problem in patenting a biotechnological process to produce the genetically modified organism, or the application 
of such a process, since the inventiveness is the application 
or the process, not the gene itself. A genetic sequence should 
not be patentable, but only its application, suc h as the 
production of a new therapeutic drug. 
Products of nature and products of industry must be distinguised. What is natural creation and what human invention must not be lost. If a living creature is God's 
creation then it is due respect. It is wrong in principle to patent living organ1sms as these owe their creation to God and 
not to human endeavour. 35 
"It is abhorrent that the information relating to any aspect 
of the human body should be seen as intellectual property." 36 
"The religious critique of biotechnology and the patenting of life focuses on our ability to override or oblite rate the distinctions between life and matter, nature and technology, humanity and God on which our spiritual estate seemed to depend - distinctions that helped us think that man belongs to 
nature, not the other way around." 37 
Protection from commercial abuse and protection of investment 
should not supercede human dignity and universal a ccess to 
what is natural. 38 
E. Concluding Comments 
In 1990 the United States government began work on the Human Genome Project, estimated to take fifteen years and cast three bi 11 ion dollars. Then in the Spring of 1998, an Amer ican 
scientist, and an American pharmaceutical c ompany formed a 
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company with the purpose of cataloguing most of the genome in 
three years at a cost of three hundred million dollars. 39 
Fear that the private company will obtain most of the gene 
based patents has led officiais at the National Human Genome 
Research Institute to reconsider their approach, and produce 
a rough draft of the gene catalogue rather than the definitive 
one originally planned. So that everyone will have a chance at 
the patent rights rather than permitting one persan or group 
to have a dominant position, complete accurate detail is to be 
sacrificed to speed. Ownership of patent will go to he who is 
the swiftest and gets there first. 
It seems likely that modified donor animal organs will be 
patentable. What about the donor animals themsel ves? Who 
will own them? How will such a monopoly affect priee and 
affordability? How can distributive justice prevail under 
such circumstances? 
That we ar~ able to crea te 1 ife 1s awesome; that we are 
permitted to patent life, frightening; that we require legal 
regulation, urgent. 
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CHAPTER 6 - IS A MORATORIUM NECESSARY? 
1. INTRODUCTION 
The technology resulting from scientific endeavour and 
discovery permits us to intervene increasingl y ln fields 
hitherto thought untouchable. There may be a prac ti c al need 
and adequate justification for xenotransplantation. Howev e r, 
ethical, social and public health issues remain unreso lved, 
and both recipient and society appear to be at risk. Not o nl y 
must the safety of the individual and of all societ.y be 
ensured, but the underlying morals of our s ociety with reg a rd 
to commercialisation of life must be respected. 
The question being asked 1n the s c ien t ific and medi c al 
community is whether there should be a moratorium on clinic al 
xenograft trials. Those who answer yes are fearful of the 
risk to patient and public and concerned about the eth ical 
implications; those who answer no are motivated by the 
unquestionable need and by the number of deaths of those 
awaiting organ transplant. Effort must be directed towards 
balancing these legitimate concerns. 
We have asked whether, g1ven the current status of risk and 
knowledge and given the existing legal framework, we should 
impede scientific progress and withhold therapy from those in 
need. To reply, it 1s necessary 
xenotransplantation both in the context of 
protocol, and as innovative therapy. 
2. EXPERIMENTATION 
to c onsider 
an experimental 
Research through experimentation 1s a scientific a c tivity 
oriented towards the accumulation of knowledge accruing for 
the bene fit of society. It 1s an organized process wi th 
predetermined and specifie procedures described in a deta i led 
protocol and carried out on designated subjects in order to 
test an hypothesis. The resul ts and data obtained can be 
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statistically assessed for valid scientific significance 
contibuting to additional knowledge. Although it is hoped that 
the subjects will benefit, the main goal, 1s an accumulation 
of knowledge. Direct benefit to the subject is desirable, but 
secondary. 
Multiple laws, regulations and guidel ines exist to protect 
both animais and human subjects in experimentation. An Ethics 
committee assesses the protocol to determine whether all 
conditions, including a favourable risk\benefit ratio, have 
been fulfilled, and to ensure that the consent of the human 
subjects has been validly obtained. 
3. TREATMENT 
Treatment 1s oriented towards improving the state of an 
individual. It does not function according to a protocol but 
rather in accordance with the needs of the individual as 
assessed by the physician. The objective 1s not general 
scientific knowledg e but treatment and cure of that particular 
patient. However, treatment may unexpectedly lead to 
important scientific discovery, just as a research procedure 
may prove effective 1n the treatment of the particular 
subject. 
4. INNOVATIVE THERAPY 
Nowhere is the term "innovative therapy" defined i n law. The 
fourth paragraph of Article 21 of the Civil Code of Quebec 
provides that it is up to the Ethics Committee to determine 
whether or not "care" . is innovative therapy. Th e treatment 
must be care "required by the state of health of the person 
submitted to it". Once labelled by the Ethics Committee as 
innovative therapy, the procedure is held not to constitute an 
experiment, thereby withdrawing it from the requirement of 
examination by the Ethics Committee. By definition, 
"innovative therapy" must at ]east be therapy, and it 18 
unlikely that any drastic deviation from normal medical 
3 
practice, such as xenotransplantation surgery, 
considered. 
would be so 
5, DISTINCTION BETWEEN INNOVATIVE THERAPY AND EXPERIMENTATION 
A. MRC Guidelines 
The MRC Guidelines on Research Involving Human Subjects 
state: 1 
"The patient is always entitled to the best clinical judgment 
of the physician, and research considerations must never 
displace this. This is true even if the patient requires 
innovative treatment that, while therapeutically appropriate, 
1s also of research interest. Since the innovation 1s 
intended for the patient's therapeutic benefit, the treatment 
1s not research even though the resul ts may be of wide 
interest and benefit." 
Such statement 1s compatible with the obligations of the 
physician to practice according to the highest current 
standards 2 and in accordance with scientific principles 3, 
and to avoid unreasonable acts or acts not in conformity with 
current medical knowledge 4 or not yet medically proven. 5 
B. The Law Reform Commission 
The Law Reform Commission in its Working Document No. 61 6 
has no problem differentiating between scientific research and 
therapy, but finds it difficult to define "experimental 
treatment" which 1s a contradiction 1n terms. It 1s a 
treatment, that is, a procedure performed for the benefit of 
a particular patient, which has not yet fully proven itself 
scientifically. There is consequently uncertainty as regards 
results which legally and ethically require precaution. Also, 
the legal requirements regarding divulgation of risk and the 
information given for consent are different. The 
commissioners conclude therefore that to qualify an act as 
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"therapeutic research" is both 
Imprecise 
dange rous 
because 
because 
the 
the 
treatment 
imprecise and dangerous. 
is not yet therapy and 
chief role of the experimenter lS 
research and not therapy. 
patient as well. 
This can be misleading for the 
The commissioners side-step the issue and concentrate on the 
distinction between treatment and experimentation 
use the term "therapeutic research" and 
"experimentation" 
. t t. " 7 exper1men a 10n . 
as 
c. The Belmont Report 
A distinction lS made 
"non-therapeutic 
the Belmont Report 
refusing to 
qualifying 
biomedical 
s between 
"practice" defined as an intervention "designed solely to 
enhance the well-being of an individual patient o~ client and 
that has a reasonable expectation of success", and "research" 
which "designates an activity designed to test an hypothesis, 
permit conclusions to be drawn, and thereby to develop or 
contribute to generalizable knowledge ... ". Innovation does 
not, in and of itself, constitute research. The fact thaL a 
procedure is "experimental" in the sense of new, untested or 
different, does not automatically place it in the category of 
research." The report does suggest, however, that radically 
new procedures be made the object of forma! research at an 
early stage to determine safety and effectiveness. " ... the 
general rule is that if there is any element of research in an 
activity, that activity should undergo rev1ew for the 
protection of human subjects." 
D. The Government of Quebec 
The Minister of Health in his recent report on research ethics 
9 and scientific integrity attempts to define "innovative 
therapy" and to distinguish it from accepted treatment and 
experimentation. Therapeutic procedure refers to treatment 
which has been established and proven; experimentation refers 
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· 1 ff . lS unknown and which to a procedure whose clin1ca e 1cacy · can only be used as part of an approved scientific protocol . Innovative procedures have passed the experimental stage, but have not yet benefited from the experience of use. Consequently, although they have been shown to work, they have not yet been tried on a variety of subjects, in differing circumstances, or under varying conditions. Their efficacy is established but conditions of their use and application remain 
undefined. 
6. THE PHYSICIAN'S DILEMMA 
Scientific researchers are governed by local common law and various guidelines, in addition to which physician researchers are also governed by their own professional code of ethics . 
Does a physician have the right to innovate? If so under what circumstances and under what conditions? Certainly any innovation must be well grounded scientifically and performed with caution . Can it ever be justified where the potential of widespread nefarious effects are even a remote possibility as would be the case with xenotransplantation? 
What about the professional liability of the physician; under what conditions and circumstances would it be engaged? To what extent must the patient be advised of the possible risks invol ved? At what point does the physician breach his obligations of care, beneficence and professionality by using an untried or little tried technique or therapy? 
Is it necessary or advisable to define when deviation from standard practice becomes innova ti ve? 1 s i t necessary or advisable to define when innovation should be attempted? When and under what conditions should such procedures be permitted? How should such procedures be reviewed? Should review be necessary? Since ethics committee approval is not required, who should approve? Is the decision of the treating physician sufficient? What happens when innovative therapy fails and 
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another treatment exists? 
How would these questions apply to xenotransplantation, and 
how would they be answered in this situation so frought with 
scientific, legal and ethical problems? It appears obvious 
that a physician would be in violation of his Code of Ethics 
were he to attempt to justify performing a cross species organ 
transplant on the grounds that it is "innovative therapy". 
But this is no reason to prohibit all experimentation in this 
field. It . is justificètion, however, for requiring stringent 
controls. Furthermore, the Declaration of He lsinki r e quires 
that the procedure be tested successfully on animals first, 
and there · can be no justification for a protocol using human 
subjects until such time as results are available indicating 
success with xenotransplantation between animals. When that 
time cornes, there already exists a substantial body of laws 
and regulations which can be modified and extended so as to 
control procedures involving genetic modification and 
xenotransplantation. 
7. THE LEGAL FRAMEWORK 
A. Consent 
Both animal and human research subjects are protected by 
numerous regulations and guidelines, and humans must first 
give free, enlightened and voluntary consent to any procedure 
to be practiced upon them. In a society which recognizes the 
autonomy of the individual and veers away from any sign of 
paternalism, any human subject who opts to take the risk of 
xenotransplantation rather than accepting the risk of imminent 
death, must be free to do so. However, individual freedom and 
autonomy are limited by the rights of others and the common 
well being. Consequently, provision will have to be made for 
obtaining the collective consent to or refusal of society in 
general to xenotransplantation. 
Consent w1· 11 take · · h on new mean1ng w1t transplantation. 
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Recipients, 1n addition to the provisions t o wh ic h they must 
now agree, will have to consent to b e mo ni t o red o n a 
continuing basis, and probably to isolation as we ll. Th ey 
will have to understand that, should th ey s urv1 v e , s uc h 
monitoring and isolation would affect their quality o f life , 
as well as their privacy, and their right t o conf i d e ntia l ity 
protection would be limited. They will then b e fr e e to c hoose 
between a constricted life style and no l i f e at a ll. Thei r 
families will have to be made aware of all risks o f c ontac t, 
and consent to the limits pla c ed thereo n s o that t he publ ic 
may be protected against the possibility o f i nfection. 
B. Risk 
Clarification of risk can be undertaken by furth e r researc h 
into the transmission of infectious organisms between swine 
and man. Control can be exercised through regulated breed i ng 
pract ices, frequent testing of do nor anima 1 s, as well a s 
monitoring of and strict vigilanc e over human recipients to 
which the latter will be obliged to consent. The public will 
need to know what dangers exist, their nature and probab i l ity 
of occurance, and to what extent protection c an be accorde d. 
Clinical trials will use as their first human subjects those 
who have no hope, and for whom the status of research subjec t 
or patient will not be relevant. The various AlOS trials wer e 
not rouch different. The side effects, both known a nd unknown, 
of new drugs and combinations of drugs, were so horrible it 
was often impossible to calculate a risk / benefit ratio. 
Still, not only did AlOS patients agree to act as subjects, 
they begged to do so. At such time as xenotransplantation can 
be performed with sorne chance of success, it will give meaning 
to the term "innovative therapy". 
8. ETHICAL CONCERNS 
There rema1n the ethical concerns both with regard to the 
animal and wi th regard to the human. It may be less than 
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ideal to breed pigs as organ donors, but if they are well 
treated and killed painlessly, and if genetic manipulation is 
strictly limited to what is necessary for the success of the 
procedure and in no way affects or hurts the animal, how can 
we argue against their use in this way when we think nothing 
of eating and wearing them. At such time as there 1s an 
alternative way of replacing a _failed organ, there may be a 
valid ethical argument against xenotransplantation. However, 
at the present time, given the general behaviour patterns of 
our society,, there isn't one. 
Ethical issues pertaining to equal respect for and evaluation 
of all life' regardless of developmental capacity and to the 
potential for m1suse of the developing technology are 
especially evident with patenting. Genetic manipulation has 
resul ted 1n patenting, patenting gives commercial control 
creating a fear of exploitation and discrimination between 
those who can and those who cannat afford to purchase the 
commodity. 
A. Genetic Modification 
If genetic changes to the donor animal are minimal, do not 
hurt or alter the character of the animal, and pertain only to 
that which is necessary for a particular treatment, they are 
surely no worse that spaying animais in order to limit their 
reproductive capacity. What is to be done is spelled out in 
a protucol which is considered by an ethics board and is peer 
reviewed. The researcher's freedom can be further limited by 
the creation of national specialized review boards to review 
all protocols which include genetic modification of animais. 
The CCAC Guidelines provide adequate protection to the animal 
in the context of institutional research. It 1s control 
through application of law such as now exists in Prince Edward 
Island, Nova Scotia, Manitoba and Ontario, and not a 
moratorium, which is required for the protection of society. 
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B. Patenting 
The 1ssue o f patent i ng o f lif e f o rms must be ress o lved between 
the courts and the lawmakers. Biotec hn o l ogical ac h ieveme n t 
has brought to light a n area o f the law whi c h needs to be 
updated. In our society, creation of forms o f life is equated 
with a power which should o nly be attributable to God . Th e 
Patent Acts of different countries requ 1 r e ame ndmen t to 
address these 1ssues, but such requirement should not be 
permitted to impede scientific progress . 
9. CURRENT STATUS OF MORATORIUM ON CLINICAL TR IALS 
Early in 1999 the Counc il of Europe's Parl iamentary Assembly 
issued a report calling for a mo ratorium on c lini ca l trials of 
xenotransplantation. 
opposed by Spanish 
Xenotransplantation, 
This has been vehemently cr i ticized and 
scientists, the Spanish Commission on 
the Spanish Ministry of Hea lth and the 
European Council's Transplantation Commission. JO 
In the United States, the Food and Drug Administration has 
drafted the xenotransplantation guidelines already discuss e d 
in chapter 3 , and has approved Phase 1 c linical tr ia ls f o r 
transplanting fetal p1g neural cells into patients with 
Parkinson's disease. 11 
In Great Britain a moratorium on clinical tri a ls was put in 
place as of January 1997 following the recommendation of the 
]? Advisory Group on the Ethics of Xenotransplantatio n. -
Canada, on the 
xenotransplantation 
other 
trials, 
hand, 
but lS 
has not prohibited 
rather 
international leader in xenotransplantation" . 
"becoming an 
13 Agreements 
have been reached between Toronto, Guelph and Western Ontario 
Universities and the pharmaceutical company Novartis to 
develop xenotransplantation. However, there are no clinical 
trials in progress. 
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CONCLUSION 
There may always be those who will disagree with 
xenotransplantation on ethical grounds even if it becomes an 
accepted treatment. The Japanese conception of the human 
being is one of unity of body and soul . Consequently , they do 
not consent to harvesting organs when the body continues 
breathing and warm. They also do not permit experimentation 
on animals, or on embryos , nor do they allow genet ic 
manipulation. In spite of the new biomedica l technologies, 
they have maintained their traditional approach by which 
health is a balance, a harmony to be achieved. 1 
Where conf 1 ict ing va 1 ues ex ist, an attempt may be made to 
ressolve the resulting dilemmas by creation of ethical rules 
which evolve through exercise of judgment roote d in subjective 
perceptions. One such societal value leads us to try, as a 
society, to grant equal medical care to everyone; 
unfortunately we are not always successful. The reality is 
that the current expenditure on allografts 1n the United 
States is 2.9 billion dollars per year, and it is estimated 
that if all needed organs were available this would increase 
to 20.3 billion dollars. Commercialization may be necessary 
to attain affordability, but we must assure that it does not 
lead to exploitation as this would prevent transplantation 
from being equally available to all. We must insist that 
profit be achieved within an appropriate, acceptable, adequate 
and enforceable legal and ethical framework. 
Laws already exist to protect both human and animal subjects 
of scientific experimentation. But these must be extended to 
apply to all experimentation and not only to that carried out 
in specifie institutions or funded by particular agencies. 
The possible ramifications of uncontrolled privately funded 
research demands that a system of oversight be established, 
and until that is done the fear of potential disaster due to 
advancing biotechnology will be justified. 
2 
Furthermore, the law has not kept up with the rapid advances 
in genetic research and this must be addressed without delay. 
Only by control through the justice system can we guarantee 
against the creation of freaks of nature, and the exploitation 
of life forms. 
In our own society it 1s the law which places boundaries on 
behaviour, and i t 1s that law which must be amended and 
expanded in order to provide a stronger framework within which 
biotechnological research can proceed. Then, whi le 
recognizing that xenotransplantation cannot yet be accepted as 
a treatment or as innovative therapy, the research can 
continue without fear of its eventual application. 
Victory over sickness and death will not come easily, if at 
all. Taking into consideration our fear of the unknown as 
well as our desire to live forever, perhaps we could find 
guidance by adopting, mutatis mutandis, the prov1s1ons 
'J 
contained in the Canadian Charter of Rights and Freedoms~ and 
imposing on the freedom of scientific investigation such 
reasonable limits as can be demonstrably justified 1n our 
technologically advanced, and 
society. The proportionality test 
context of scientific research 
commercially competitive 
may then be applied in the 
so that the interests of 
society are balanced with those of the individual, and those 
of the scientist with those of his subject. While scientific 
ingenuity in attaining a desirable goal cannot be permitted to 
outweigh risk to society as a whole, so long as that risk 1s 
controlled, scientific discovery should not be smothered. 
It is the method used 1n the pursuit of knowledge which must 
be regulated. Because the demand for organs exists, there are 
those who will attempt to fulfill it. Legislation for animal 
and human subject protection must be extended to all research, 
and provided with appropriate sanctions 1n the event of 
violation. Compulsory and effective peer review as well as 
Ethics Committee approval of protocols can ensure that a step 
by step approach is used with provision for frequent follow up 
3 
and review. That way the procedure of c r o ss spec1e s 
transplantation can be c losely monitored without preventing 
the researc h. The need for international regulation 1s 
recognized as being of utmost importance as we ll, as viruses 
travel easily between countries without visa requirements. 
Betsy MacGregor, coordinator of Industry Canada ' s National 
Biotec hnology Advisory Commitee, has expessed the desire of 
Canada to have an international panel give its opinion on how 
the issues relating to xenotranplantation are to b e cop e d wit h 
on a national level, especia lly since the societ.al risk in 
. t. 1 3 1nterna 10na . 
Even without the necessary amendments to the law, it would be 
in violat ion of existing law, regulati o ns, guide l ines, and 
medical ethics codes to perform xenotransplantation as 
innovative therapy on any human patient at the present time , 
and it would be totally unethical for any IRB or ERB to 
approve any research protocol for testing the process with 
human subjects at this time. But as animal research 
continues, the time for clinical trials with humans will 
arrive, and all protective legislation should be in place so 
that they can begin. 
At this stage, xenotransplantation is not a treatment option 
for patients. However, this does not require a moratorium on 
c 1 inical tria 1 s, but rather i 11 ustrates the nec essi ty for 
legislative amendment. Much work is being done on all aspects 
of xenotransplantation and the time will come when the trials 
should begin. Before such time, the problems of zoonosis wi ll 
have to be resolved, or at least controlled, reducing the risk 
bath to the recipient and the public in general, trials on 
ether species, including primates, will have to be ca rried 
out, and proper controls must be in place for protection of 
all parties. 
Given the current state of knowledge and the ethical problems 
associated with xenotransplantation, it is reasonable to ask 
whether the situation calls for a moratorium on clinical 
4 
trials as presently exists in England, Sweden and Germany. 
After all, alternatives do exist; namely, crea te a law of 
presumed consent to organ donation in arder to boast the low 
rate of cadaveric donations, encourage healthy life styles, 
work on immunosuppressants, artificial organs, and the 
grafting of cell and skin tissue from human embryonic stem 
cells. 4 
Dr. Calvin Stiller, Chief of the Multi-organ transplant 
service at University Hospital in London, Ontario , states: 
"The science of organ transplantation like nuclear 
science, must be accountable to society. It cannat stand 
alone, with an open mandate to do what it wants as long 
as there is progress. Progress defined exclusively as 
the improvement of technical skills may not be progress 
at all." 5 
This may be so, but it is not a moratorium which is necessary. 
The present legal structure makes it illegal to perform 
xenotransplantation on humans at the present time. If 
expanded to apply to genetic research and to include all 
researchers, and if given the power to sanction transgression, 
it would provide sufficient protection from misuse of the 
technology. Furthermore, the public would be best served by 
encouraging the continuation of research in this area while 
being advised of the limitations, possible ramifications and 
ethical aspects. In that way, one step at a time, the 
research into xenotransplantation can proceed, its use to be 
restricted and overseen by law and its potential possible 
effects to be understood by a protected public. Only at the 
end of this voyage will it be possible to sanction 
xenotransplantation as treatment. The public will be better 
served by the continuation of that voyage than by the 
imposition of a moratorium. 
5 
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